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ABSTRACT 
A NOVEL INTERVENTION TO PREVENT POST-TRAUMATIC 
OSTEOARTHRITIS FOLLOWING KNEE JOINT INJURY 
SEPTEMBER 2021 
GERARDO E. NAREZ, B.S., UC SAN DIEGO 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Tammy L. Haut Donahue 
The knee joint is the most commonly injured body part in the human body. Injuries 
as a result of participation in sports, or other recreational activities, often leads to damage 
to the anterior cruciate ligament (ACL) and meniscus. Injury to these tissues are strongly 
associated with subsequent knee post-traumatic osteoarthritis (PTOA), which is considered 
a serious disease because it greatly impacts a patient’s quality of life and significantly 
increases their risk of premature death. To return stability to the joint, the current clinical 
treatment is to perform reconstruction of the torn ACL and a meniscal debridement, or 
meniscectomy, when needed. However, long term studies have shown that surgical 
intervention does not prevent the onset or progression of PTOA. It is believed that 
reconstruction surgery fails to address the occult damage to the soft tissues within the knee 
joint at the cellular level. Recently, a single dose of the amphipathic and nonionic surfactant 
Poloxamer 188 (P188) has been shown to be an effective inhibitor of acute cell death and 
inhibit pathways associated with inflammation in articular cartilage in both in-vitro and in-
vivo studies. 
vii 
This project strives to test if combined surgical and P188 treatment following injury to the 
ACL will help prevent PTOA in an in-vivo closed-joint traumatic injury model. It is 
hypothesized that combined treatment will mitigate or delay the progression of the disease 
joint by returning normal knee kinematics and restoring the integrity of damaged cell 
membranes in the soft tissues. Thus, the aims of the proposed project are to: 
1) Determine the efficacy of a single and multiple temporal administrations of P188
in inhibiting cell death following traumatic impact in meniscal tissue.
2) Assess morphological, functional and histological changes in the meniscus
3) Evaluate chronic changes in subchondral cortical and trabecular bone of femurs and
tibias
4) Determine the presence of biomarkers associated with PTOA in the synovial fluid
Finding solutions to prevent the onset of PTOA, in conjunction with ACL reconstructive 
surgery, would provide a novel treatment to improve the quality of life for millions of 
people and decrease their risk of premature death.  
viii 
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The knee is the most complex joint in the human body that is composed of 
various hard and soft tissues. The four bones, hard tissue, found within the join include 
the femur, patella, tibia and fibula. Subchondral bone is the layer of bone found directly 
beneath the articular cartilage, separated by a zone of calcified cartilage, and extends to 
the growth plate of the femur and tibia.55 (Figure 1) This region consists of both 
nonporous cortical bone and spongy trabecular bone. Bone is an adaptive tissue that 
remodels itself and responds to mechanical stimulus from every day use. During this 
process, osteoclasts first resorb bone and osteoblasts then go through a phase of bone 
formation.159 In normal physiological conditions, the amount of bone removed during the 
resorption phase is balanced by the bone formation phase, such that bone mass is 
Figure 1. Anatomy of the main bones found in the knee joint and the area defined as 
subchondral bone. 
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maintained although the shape and architecture of bone is modified in response to repair 
micro-damage to the bone during mechanical loading.55,159 
The main soft tissues within the joint include the anterior cruciate ligament 
(ACL), posterior cruciate ligament (PCL), medial collateral ligament (MCL), lateral 
collateral ligament (LCL), the patellar tendon, two menisci, articular cartilage, and the 
synovium. (Figure 2) The four ligaments connect the femur to the tibia and aid in 
preventing anterior, posterior and translation movements between the two bones. The 
ACL and PCL are located in the center of the joint, or the intercondylar fossa. The ACL 
primarily functions to prevent excessive anterior movement of the tibia relative to the 
femur during normal knee motion.21 It is composed of two functional bundles; the 
anteromedial bundle which becomes taught at 90 degrees if flexion and the posteromedial 
bundle which becomes tight during full knee flexion.4,34 The PCL primarily functions to 
prevent posterior translation of the tibia relative to the femur.3 Both the ACL and PCL 
also aid in preventing internal and external rotation.3,21 The MCL and PCL connect the 
Figure 2. Anatomy of the main soft tissues found in the knee joint. 
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tibia to the femur on the medial and lateral side of the knee joint, respectively and aid in 
preventing valgus and varus rotation.84,167 The four ligaments are primarily composed of 
collagen bundles that give them their mechanical structure to stabilize the joint. 
Articular cartilage covers the ends of long bones and its primary function is to act 
as a smooth, lubricated lining between joint surfaces to facilitate load transmission. 
Chondrocytes are the main type of cell found within articular cartilage and they are 
responsible for creating the dense extracellular matrix (ECM); which is composed of 
water, collagen, proteoglycans and other non-collagenous proteins.18 Through negative 
electrostatic repulsions forces, proteoglycan molecules help retain water within the ECM. 
This feature ultimately gives articular cartilage its biphasic properties, which give the 
tissue its unique response to tensile, compressive and shear forces.111,113  
The menisci are two crescent shaped, fibro-cartilaginous structures that provide 
congruency between the tibial plateau and the femoral condyles.52 Similar to articular 
cartilage, the fibrochondrocytes found in the menisci produce an ECM, primarily 
composed of collagen and proteoglycans, which retains water and gives the tissue its 
biphasic mechanical properties.111 The primary function of these tissues are to increase 
congruency, maintain stability, and distribute compressive loads into hoop stresses, 
which also allows them to protect the underlying articular cartilage.163   
The synovium, or synovial membrane, is the soft connective tissue layer that lines 
the inside of the joint capsule. It is composed of two layers – the outer layer (subintima) 
and the inner layer (intima). The subintima contains blood vessels, which allows it to 
nourish and maintain knee homeostasis by removing metabolites and other products of 
matrix degradation.89,143 The cells found within the intima are called synoviocytes and are 
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highly metabolically active. The synovium is where the synovial fluid is produced, which 
a viscous fluid that lubricates and nourishes the tissues found within the joint capsule.143  
Due to the enclosed knee capsule surrounded by the synovium, most of the soft 
tissues found within the joint are avascular, giving these tissues limited ability to heal and 
repair themselves. Therefore, both macroscopic damage and biochemical alteration of 
these tissues can have adverse effects on their integrity and can trigger other pathways for 
further tissue degeneration.  
Knee Injuries and Post-traumatic Osteoarthritis 
The knee joint is the most commonly injured joint in the human body. Acute joint 
trauma to the joint is a result from excessive joint forces, which are caused by 
participation in sports, jump landings, or other recreational activities, and often lead to 
damage and tearing of the ACL and meniscus.62,98,119 Injury to these soft tissues are 
highly associated with the onset and progression of post-traumatic osteoarthritis (PTOA), 
a secondary form of osteoarthritis (OA).38,39,44 PTOA is more commonly documented in a 
younger, more active population and it accounts for 12% of all patients exhibiting OA in 
the US with a financial burden of $2-3.06 billion dollars annually.17 It is important to 
note that although the mechanisms that lead to the onset of each disease are different, 
they both have the similar end stage result.  
 PTOA is known to negatively impact the meniscus, articular cartilage, 
subchondral bone and synovium of the knee due to the damage and inflammatory 
response due to the initial trauma and subsequent changes in load distribution.54 (Figure 
3) In both the meniscus and articular cartilage, the disease is known to cause a fibrillation 
and damage to the surface, decrease in the mechanical properties, and a deterioration of 
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the solid matrix.103 Previous studies have shown that in a process known as 
mechanotransduction, a cells response to mechanical stimulus, chondrocytes in the 
articular cartilage respond to the changes in loading pattern and begin to go through a 
process of ossification.33,56 This ultimately leads to an increase in the advancement of the 
tidemark and eventual thinning and loss of the tissue, accelerating osteoarthritic changes 
in the joint. These changes are more commonly observed in the medial compartment of 
the joint compared to the lateral compartment.  
As previously mentioned, bone is an adaptive tissue that goes through stages of 
remodeling and modeling as a response to mechanical loading, therefore changes in 
loading pattern as a result of alterations to bone contour during articulation can cause 
changes in bone architecture and mineral content. In subchondral bone, PTOA/OA is 
associated with the formation of osteophytes (bone spurs), a decrease in bone mineral 
density, and an increase in cortical bone thickness. Osteophyte formation is thought to be 
caused by alterations in joint mechanics and are commonly the first trademark sign of 




PTOA observed in the knee joint. PTOA is known to disrupt the normal remodeling and 
modeling stages of bone, which can cause rates of bone resorption being high and rates of 
bone formation being low, leading to hypomineralized bone. These changes in bone 
mineralization affect the overall size and shape of subchondral bone that can also lead to 
a change in joint loading and further progress the disease.  
A healthy synovium produces soluble mediators including, cytokines, 
chemokines, eicosanoids, and free radicals, to maintain homeostasis of the joint.143 
Following trauma to the joint, the synovium goes through an inflammatory response to 
protect the joint from further injury, eliminate the stimulus, and promote repair of the 
affected tissues. Inflammation of the synovium that occurs as a result of PTOA is referred 
to as synovitis.  Synovitis causes the synovium to overproduce and release soluble 
mediators that promote solid matrix degradation in soft tissues through a positive 
feedback loop that increases cartilage damages and impairing repair, resulting in a 
vicious cycle.89,139,145,147 Some of the pro-inflammatory mediators strongly associated 
with OA include, but are not limited to; interleukins (IL-1β, IL-6, IL-8 and IL-15), 
monocyte chemoattractant protein (MCP-1), tumor necrosis factor (TNF-α), macrophage 
inflammatory protein (MIP-1γ), and interferon (IFNγ).146 These mediators, produced by 
the synoviocytes, interact and communicate with the other tissues in the knee joint, 
causing further degradation and increasing the severity of OA.  
As of 2016, the Food and Drug Association (FDA) has classified OA/PTOA as a 
severe disease because it greatly increases a patient’s likelihood of living with other co-
morbidities, decreases life expectancy, and ultimately reduces the patient’s quality of 
life.121 Currently, there are no known effective treatments for OA, with the only FDA 
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approved treatment involves using non-steroidal anti-inflammatory drugs (NSAIDs). 
However, NSAIDs can have adverse side effects and even lethal in patients who suffer of 
cardiac problems, which is one of the co-morbidities strongly associated with OA.121 
Therefore, there is a need for better treatment options to delay or prevent the onset of 
OA/PTOA.  
Current Treatments  
 The most common treatment to repair damage or a tear in the ACL or meniscus 
involves surgical intervention to both tissues. The goals of the surgery are to return 
normal kinematics to the joint and delay or prevent the onset of PTOA. Each year in the 
US, between 100,000 and 400,000 patients undergo ACL surgeries, with total costs on 
the order of $2 billion US dollars.32,58,166  
In an ACL reconstruction surgery, the torn and damaged tissue is removed and it 
is replaced with a tendon graft harvested from the medial hamstring, the middle third of 
the patellar tendon, or allograft tissue. After choosing the appropriate graft for the patient, 
the surgeon performs a diagnostic arthroscopy to determine if any damage occurred to the 
menisci and the articular cartilage. If damage to the meniscus is observed, a meniscal 
debridement is performed to remove any portions of damaged or torn meniscus. This 
procedure is often referred to a meniscectomy. Following debridement of the meniscus, a 
small incision is made into the knee joint and tunnels are drilled into both the 
intercondylar fossa of the femur and tibial plateau along the point of insertion of the 
native ACL. The graft is then fed through the tibial bone tunnel and then through the 
femoral bone tunnel and it is anchored at the bone ends using a Nitinol pin. Prior to fixing 
the graft to the tibia, it is often rotated to mimic the 90 degree rotation in the collagen 
 
21 
bundles of the native ACL. Once the graft is anchored, the knee capsule is sterilized and 
closed. The amount of tension placed on the reconstructed ACL varies between surgeon 
and the graft used to recreate the reconstructed tissue and has a direct effect on 
rehabilitation following surgery.100,106,112  
ACL reconstruction has been shown to be effective in restoring the sagittal plane 
stability to the knee,106,112 however multiple studies have reported that surgical 
intervention does not appear to significantly decrease the risk of developing PTOA in the 
joint.51,94,131 Some studies have shown that regardless if patients undergo surgical 
intervention or not, 78-83% will develop PTOA 10-14 years post-surgery, and the 
prevalence of the disease increases if ACL tear occurs in combination with an injury to 
the meniscus.46,131 A previous study reports that patients with damage to the ACL have a 
7-fold increase in needing a total knee replacement due to end stage OA, but that 
likelihood increases to 15-fold if there is damage to the meniscus.80   
Although the exact mechanisms that lead to PTOA following surgical intervention 
are not well understood, it is hypothesized that occult damage at the matrix cellular level 
that is not addressed during reconstruction surgery plays a key role in the onset and 
progression of the disease. Pharmaceutical intervention that mitigates the progression of 
damage at the cellular following traumatic impact may be able to help mitigate further 
damage to the joint than surgery alone, which could help prevent the onset and 
progression of the disease. 
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Poloxamer 188 (P188) 
Poloxamer 188 (P188) is an amphipathic, non-ionic surfactant that has been 
approved by the US FDA as safe for oral or intravenous administration and is excreted in 
the kidneys un-metabolized. P188 is a tri-block copolymer with an average molecular 
weight of 8,400 Da and is made of two poly(exythylene) (POE) tails and a 
poly(oxypropylene) (POP) body. The two POE chains are hydrophilic and the POP body 
is hydrophobic, mimicking the composition of the lipid bilayer found in cells. This 
composition allows the surfactant to insert itself and reseal cell membranes that have 
been damaged by electric shock, thermal damage, physical stress or chemical agents and 
is able to return normal cell membrane surface pressures.65,85,124,148 (Figure 4)  
Multiple in-vitro studies have reported that a single 8mg/mL dose of P188 
administered immediately following traumatic impact to cartilage explants was able to 
Figure 4. Life cycle of cells following traumatic mechanical injury. P188 is able to 
facilitate cell membrane resealing, inhibits pathways of secondary messengers, and 
prevents cell death. 
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significantly reduce cell death.8,9,53,118,130 Interestingly, the surfactant was shown to limit 
the area of cell death to that local to the site of initial trauma53, signifying that it could 
potentially be affecting the mediators chondrocytes were expressing and releasing into 
the ECM.9,148 Upon further investigation, it was found that P188 was able to inhibit the 
IL-6, mitogen-activated protein kinase, and GSK-3 pathways, all of which are strongly 
associated with an inflammatory response in cartilage. (Figure 1-4)  Thus, in-vitro studies 
found that P188 is able to reseal compromised cell membranes which resulted in higher 
levels of cell viability, but by doing so, it could also control the tissues inflammatory 
response, making it a promising therapeutic agent in PTOA.  
Similarly, the efficacy of the surfactant in in-vivo models has also found 
promising results.29,74,138 Two studies found that a single dose of P188 injected directly 
into the knee capsule immediately following traumatic injury to the closed joint in rabbits 
was able to reduce cell death in articular cartilage, when compared to the non-treated 
group.74,138 The results from these studies were not as promising as those from in-vivo 
studies, which lead the authors to suggest that by timing multiple administrations of the 
surfactant to cell necrosis, which happens immediately following impact, and cell 
apoptosis, programmed cell death that occurs hours or days after impact, could improve 
the efficacy of the surfactant. One in-vivo study found that the surfactant was able to 
significantly reduce proteoglycan (GAG) loss when compared to the impact only group.29 
This suggests that the surfactant is also able to prevent degenerative changes of the ECM 
in-vivo, thus further supporting the use of P188 as a potential treatment following 
traumatic impact to the knee joint. However, it remains unclear if multiple temporal 
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administrations of the surfactant would improve its efficacy and if it is able to prevent 
cell death in other soft tissues in the knee, besides the articular cartilage.  
Animal Models to Study PTOA 
Due to the complex and dynamic nature of OA and PTOA, it is difficult to study 
the etiological and progressive aspects of these diseases in humans, as only end-stage 
tissue is readily available. Therefore, translational animal models are powerful tools that 
enable a more detailed investigation into the origins and progression of these diseases. 
Induction of PTOA in animal models, with lapine or rabbit models being more widely 
used, often involves mechanical disturbances to various tissues, induced through open 
joint surgery, impact models, or some combination.12,22,47,48,99,127,162,168   
The most common technique to destabilize the knee to induce PTOA involves 
surgically transecting the ACL12,22,162 and/or a partial or full medial meniscectomy.48 
(Figure 5) Although surgical transection models induce changes to the tissues in the knee 
Figure 5. Representative images of surgical methods used to 
destabilize the knee joint to induce PTOA in animal model studies. 
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joint that are consistent with PTOA, the observed changes are often times not consistent 
with those observed in the clinical setting following a traumatic impact to the knee 
joint.108,153,154 These models fail to address occult damage to other structures including; 
cartilage, meniscus, and subchondral bone, which could skew pathological findings. It is 
also likely that these models influence synovial swelling, up-regulation of inflammation, 
and pain, all of which could affect study findings.134  
Recent advances in animal models have developed models to deliver an injurious 
impact to the closed or open joint to cause the destabilization of the knee.47,48,127 These 
models are able to cause damage to both the ACL and meniscus as well as other tissues 
the knee, making them more clinically relevant to study the onset and progression of 
PTOA. Previous studies have directly compared the closed-joint impact model to the 
ACLT model and found that the impact model showed changes in articular cartilage, 
meniscus, and subchondral bone that were more representative of PTOA.48,127 It has been 
suggested that to better study the disease, closed-joint impact models should be used over 
transection models. Currently, there are a number of studies that investigate the onset and 
progression of PTOA using a closed-joint impact model, however, no closed-joint impact 
model study has reconstructed the ACL following failure due to impact and assessed the 
soft tissues in the knee for the onset and progression of the disease.  
Multiple studies using animal models primarily focus on the degenerative changes 
in one tissue over the others, with most studies focusing on the articular cartilage. The 
pathology of PTOA should be considered as a whole joint disease, in which disturbances 
and responses from various tissues elicit and propagate degenerative responses in the 
surrounding tissues. Therefore, future studies investigating the progression of the disease 
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should evaluate degenerative changes in numerous tissues to better encapsulate the 
progression of the disease. This approach could shed light into the onset of the disease 
and provide better insight into methodologies that may aid in preventing the disease.  
Research Aims 
There exists a clear need for other treatments to prevent or delay the onset of 
PTOA following ACL reconstruction surgery, one that may address the occult damage at 
the cellular level from the initial impact. The goal of the study is to determine if 
combined targeted treatment of ACL reconstruction surgery and administration of P188 
in a closed-joint impact model will limit, delay, or mitigate the development of PTOA in 
the affected joint. In order to address this goal, the following specific aims are proposed:  
Aim 1: Determine the efficacy of a single and multiple temporal administrations of P188 
in inhibiting cell death following traumatic impact in meniscal tissue. 
No studies have documented the efficacy of P188 in meniscal tissue in preventing cell 
death following a traumatic impact and/or the efficacy of multiple temporal 
administrations of the surfactant. Meniscal explants will be harvested from Flemish Giant 
rabbits and be subjected to a traumatic impact known to cause cell death. Following 
impact, meniscal explants will be randomly assigned to one of six treatment groups to 
test the efficacy of P188 in meniscal tissue and if temporal administrations of the 
surfactant to coincide with cell apoptosis further improve cell viability. Meniscal tissue 
will be subjected to cyclic loading at 10% strain for one hour, five days a week in order 
to encourage the loading environment the tissue is accustomed to. After two weeks, cell 




Aim 2: Assess morphological, functional, and histological changes in the meniscus. 
Using a novel closed-joint and surgical reconstruction model to cause ACL failure, both 
the lateral and medial menisci will be assessed for changes associated with PTOA. 
Morphological grading will be used to determine if P188 treatment is able to prevent 
significant macroscopic degeneration of the tissue. Mechanical testing via indentation-
relaxation in a water bath will be used determine the instantaneous and equilibrium 
modulus of the tissue to assess the functional properties of the tissue. Finally, Safranin-
O/Fast Green stain will be used to determine any changes in GAG staining intensity and 
coverage of the tissue.  
Aim 3: Evaluate chronic changes in subchondral cortical and trabecular bone of femurs 
and tibias. 
Using a novel closed-joint and surgical reconstruction model to cause ACL failure, 
subchondral bone of both femurs and tibias will be assessed for changes associated with 
PTOA using micro-computed tomography. After determining the regions of interest that 
coincide with mechanical testing of the articular cartilage, both cortical and trabecular 
bone will be assessed for changes in bone quality and architecture. Parameters of interest 
in cortical bone include bone mineral density, porosity, and thickness. Parameters of 
interest in trabecular bone include bone mineral density, bone volume fraction, trabecular 
strut number, trabecular strut thickness, and trabecular strut separation. Both bones will 
also be analyzed for osteophyte formation outside the normal joint margin.  
Aim 4: Determining the presence of biomarkers associated with PTOA in the synovial 
fluid   
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Using a novel closed-joint and surgical reconstruction model to cause ACL failure, 
synovial fluid will be assessed to determine the presence of inflammatory mediators 
associated with PTOA using mass spectrometry. Following euthanasia, the synovial fluid 
from the intact knee joint will be harvested and frozen for later analysis. Once thawed, 
samples will have albumin removed using a MultiSpecies Albumin depletion column. 
Samples will then be prepared for mass spec by overnight trypsin digestion and be 
cleaned using desalting columns. The proteome of the synovial fluid will then be 
analyzed using quantitative tandem mass targeting mass spectrometry. Samples from 
treatment groups will be normalized to their respective control to account for variation in 






A SINGLE DOSE OF P188 PREVENTS CELL DEATH IN MENISCAL 
EXPLANTS FOLLOWING IMPACT INJURY1 
 
INTRODUCTION 
 Menisci are fibro-cartilaginous structures that aid in joint stability, load 
distribution and act to protect the underlying articular cartilage from large pressures in 
the knee joint. Traumatic injuries to the knee joint often lead to damaged menisci62,98,119. 
It has been long established that injuries to soft tissues of the knee can induce post-
traumatic osteoarthritis (PTOA)38,40,79,107, although the exact mechanisms to the onset of 
the disease remains unknown. Previous studies have shown that damage to the menisci 
can lead to early degeneration of the underlying cartilage31,71,102, and a 15-fold increase in 
the likelihood of a patient developing end stage osteoarthritis and undergoing total knee 
replacement80, whereby highlighting the importance of these structures within the knee 
joint. Current clinical treatment for meniscal injuries focuses on macroscopic acute tissue 
damage by removing the damaged portions, but it neglects any occult microscopic 
damage that may prove crucial in the development of PTOA. Pharmaceutical intervention 
that mitigates the progression of occult damage on the cellular level following a traumatic 
impact may be able to help mitigate further damage to the menisci and avert the 
progression of PTOA. 
_______________________________________________________________________________________________________ 
1Reprinted from the Journal of the Mechanical Behavior of Biomedical Materials, Vol. 
17, Narez GE, Wei F, Dejardin L, Haut RC, Haut Donahue TL, “A single dose of 
P188 prevents cell death in meniscal explants following impact injury”, Pages 104406, 
Copyright (2021), with permission from Elsevier.  
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Poloxamer 188 (P188) is an amphipathic, non-ionic surfactant that has been 
shown to prevent cell death in neurons86 and cartilage8,9,53,74,118,130,138. P188 is a tri-block 
polymer consisting of hydrophilic ends and a hydrophobic body, thus allowing itself to 
insert within the lipid bilayer of cell membranes to restore their integrity after physical 
stress. Previous in-vitro studies have demonstrated the ability of a single 8mg/mL dose of 
P188, administered immediately following impact, in preserving cell viability in articular 
cartilage8,9,53,118,130. Similarly, two animal impact models report that P188 significantly 
reduces the amount of cell death in articular cartilage, when compared to untreated 
groups74,138. Multiple studies suggest that timing additional P188 administrations to 
coincide with cell apoptosis would potentially improve the efficacy of the 
surfactant8,74,118,130,138. To the best of the authors’ knowledge, only one study has 
evaluated the efficacy of the surfactant on meniscal tissue. In a closed-joint animal 
impact model, Coatney et al. report that at six weeks post injection, a single intraarticular 
injection of P188 significantly helped to preserve the proteoglycan content of the 
meniscus when compared to menisci from an untreated impact group29. Although the 
study did not report data on cell viability, the results show that P188 is a viable option in 
preserving the integrity of other soft tissues in the knee joint. It is not clear if the P188 
injection directly affected meniscal changes or if it was indirectly through effects on 
other tissues in the knee joint. Thus, to better understand the actions of P188 on meniscal 
tissue directly, it is necessary to run isolated in vitro studies with isolated meniscal tissue 
to determine the direct effects of P188 on meniscus in the absence of other joint tissues. 
The current literature suggests that multiple administrations of P188 post-impact, that 
coincide with cell necrosis and apoptosis time points, may be necessary to maintain 
 
31 
meniscal cell membrane integrity following the acute injury, and potentially slowly or 
halting the progression of PTOA. 
The objective of the current study therefore is to characterize the effects of single 
and multiple temporal administrations of P188 to meniscal explants after being subjected 
to a traumatic impact. The administration time points of immediate (time 0)41, 4 days30 
and 7 days53 post-impact were chosen to coincide with previously reported high levels of 
cell necrosis and apoptosis. It was hypothesized that P188 would reduce cell death, 
thereby maintaining the biochemical integrity of the tissue similar to that of an 
unimpacted control group. This would be the first in-vitro study to assess the efficacy of 
P188 on cell viability and tissue biochemistry in meniscal tissue. 
METHODS 
 
Sample collection and treatments  
Hind limbs from ten mature Flemish Giant rabbits (5.97 ± 0.54 kg) were obtained 
following euthanasia. The study was approved by the Institutional Animal Care and Use 
Committee (IACUC) at Colorado State University. All animals were housed in individual 
cages prior to euthanasia. A biopsy punch was used to excise 2 mm diameter meniscal 
explants from both the lateral and medial menisci. Explants were then cut to 1 mm in 
height by cutting off tissue from the superficial layer using a specialized cutting tool 
(Figure 6). In order to obtain 1 mm tall explants it was necessary to take biopsy punches 
only from the outer region of the meniscus where the tissue is thick enough. The inner, 
avascular zone is too thin to obtain samples from this region. Due to differences in size 
and thickness, four explants were not always able to be harvested from each meniscus. 
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While the superficial layer has been shown to be mechanically sensitive23, this surface 
was removed to create uniform cylindrical explants with the flat distal surface. 
 Explants were equilibrated for 24 hours in culture media (88% Dulbecco’s 
Modified Eagle Medium: F12, 10% fetal bovine serum, 2% penicillin/streptomycin) in a 
humidity-controlled incubator (37°C, 5% CO2, 95% humidity). Culture media was 
replaced every two days during the experimental protocol.  
Explants were randomly assigned to one of six treatment groups, i.e. unimpacted 
no P188 (UNIMP), unimpacted P188 day 0 (UNIMP188), impacted no P188 (IMP), 
impacted P188 day 0 (IMP188), impacted P188 days 0 & 4 (IMP188-4), and impacted 
P188 days 0 & 7 (IMP188-7) with day 0 denoting immediately following impact (Table 
1). At least one explant from each animal was randomly assigned to one of the six 
treatment groups. Explants in the impacted groups were exposed to an injurious impact 
known to produce significant levels of cell death 82. Using a hydraulic testing system 
(MTS Corp, Eden Prairie, MN), explants were pre-loaded to 100mN and then subjected 
to a 50% impact strain using a ramp stroke in 1 second.  50% strain impact resulted in 
approximately 7 MPa of pressure on the explants. 7 MPa of pressure has been shown to 
be representative of a 30% meniscectomy as indicated by Zielinska et al,41. Thus this 
Figure 6. Explant harvest workflow. (A) Meniscus is harvested from Flemish 
Giant hind limbs (top and side view of meniscus body) (B) biopsy punch is 
used to collect 2mm explant plugs from the meniscus (C) explants are cut to 




level of loading has direct clinical significance. Immediately following impact, explants 
were placed in their respective media and compressed in unconfined sinusoidal 
compression using a custom-built bioreactor59,104 to 10% strain in 1 second for one hour 
per day, five days per week over a 2-week period. This level of daily loading was 
necessary for two reasons. First, it has previously been shown that unloaded meniscal 
explants in culture will start to show degenerative changes42, and secondly, previous 
studies have suggested that compressive loading and unloading helped to facilitate uptake 









At 14 days post-impact explants were removed from the culture media and a 
single 0.5mm thick rectangular cross section was collected from the middle of each 
sample (Figure 2-1). Sections of menisci were immediately incubated in 2mM Calcein 
AM and 8mM ethidium homodimer-1 (Life Technologies, Grand Island, NY) in 
phosphate-buffered saline (PBS) and incubated for 25 minutes (37°C, 5% CO2, 95% 
humidity). Images were captured for both live (green fluorescence) and dead (red 
Treatment Sample Size 
Unimpacted, No P188 (UNIMP) 22 
Unimpacted, P188 Day 0 (UNIMP188) 20 
Impacted, No P188 (IMP) 21 
Impacted, P188 Day 0 (IMP188) 20 
Impacted, P188 Day 0 & 4 (IMP188-4) 20 
Impacted, P188 Day 0 & 7 (IMP188-7) 18 
Table 1. List of the six treatment groups explants were randomly assigned to 
and the sample size per group. Day 0 represents the day explants received the 
injurious impact.  
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fluorescence) cells using a fluorescence microscope (Leica Microsystems Inc., Buffalo 
Grove, IL) at 4x magnification. ImageJ (National Institutes of Health, Bethesda, 
Maryland) was used to count live and dead cells, where the percentage of cell viability 
was defined as the amount of live cells divided by the total sum of dead and live cells. 
Data for each treatment group were averaged and normalized to the unimpacted, no P188 
group (UNIMP). 
Proteoglycan Staining  
Meniscal explants were fixed in 10% formalin. Explants were then immersed in 
30% sucrose solution for cryoprotection, embedded in Optimal Cutting Temperature 
Compound (OCT) (Sakura Finetek, Torrance, CA) and flash frozen using liquid nitrogen. 
The explants were cryosectioned to 6µm and stained for glycosaminoglycan (GAG) using 
hematoxylin, Safranin-O, and Fast Green (FCF) staining. Slides were imaged using an 
Olympus BH2 Microscope (Olympus, Center Valley, PA) and Micro-Publisher 5.0 RTV 
camera (QImaging, Surrey, BC, Canada).  Staining intensity was graded similar to 
previous studies with no Safranin-O staining represented by a score of 0, slight staining = 
1, moderate staining = 2, and strong staining = 3 (Figure 7)29,49,126. Reported intensity 





GAG staining was analyzed using ImageJ. Briefly, total area of the section was 
calculated using the ‘Analyze Particles’ tool and summing particles. The area stained red, 
or the area associated with GAG coverage, was separated from the image using the 
“Colour Deconvolution” tool137. The percent area of GAG stain coverage was calculated 
as the total area of GAG stain coverage divided by the total area of the section multiplied 
by 100 (Figure 8)29,49.  
Cell Apoptosis  
Cell apoptosis was assessed using the DeadEnd Fluorometric TUNEL Kit 
(Promega Corporation, Madison, WI). Briefly, tissue sections were washed to remove 
excess OCT and fixed in 4% paraformaldehyde. Tissues were then treated with 20µg/ml 
proteinase K in PBS for 3 minutes and then rinsed in PBS. Sections were incubated in an 
incubation buffer that included fluorescein-12-dUTP for one hour (37°C. 5% CO2, 95% 
Figure 7 Safranin-O and fast green staining intensity grading. 
(A) No stain = 0, (B) slight staining = 1, (C) moderate staining = 
2, (D) strong staining = 3. 
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humidity). Tissues were then stained in a 1µg/ml solution of propidium iodide in PBS. 
Images were captured for TUNEL positive apoptotic (green fluorescence) and total (red 
fluorescence) cells using a fluorescence microscope at 4x magnification. ImageJ was 
used to count TUNEL positive and total cells, where the percentage of apoptotic cells 
was defined as the number of TUNEL positive cells divided by the number of total cells. 
Data for each treatment group were averaged.  
Statistics 
Statistical data analysis was performed using Minitab (Minitab18, State College, 
PA). Statistical significance was assessed for cell viability using a one-way analysis of 
variance (ANOVA) with Tukey’s post-hoc test after normalization to the UNIMP 
treatment group. Comparisons for GAG intensity, GAG coverage, and cell apoptosis 
were made using a one-way ANOVA with Tukey’s post-hoc test.  Differences 
corresponding to a p-value of less than 0.05 were considered to be statistically 
Figure 8. Representative images showing the image analysis for calculating GAG 
area coverage using ImageJ: (A) stitched and trimmed image of explant was 
imported, (B) threshold and analyze particles of tissue section was used to 
determine overall area of cross section, (C) colour deconvolution tool was used to 
isolate area stained for GAG from imported image, (D) analyze particles was 
used on the colour deconvolution image to determine area of GAG coverage.  
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significant. A post hoc power analysis powered the study at 89%. To reduce animal to 
animal variability, data was normalized to unimpacted groups. Additionally, to ensure 
independence between the samples and measured outcomes, multiple linear regression 
was used with animal, limb, hemijoint, and region as explanatory variables using R (R 
Core Team, 2019).  
RESULTS  
A single impact of 50% strain significantly decreased (p < 0.05) the amount of 
viable cells in the impacted menisci compared to the unimpacted explants (Figure 9). 
This decrease in cell viability was reversed when impacted explants were treated with 
P188.  No significant differences were documented between the UNIMP explants and the 
impacted explants that received single or multiple administrations of P188 after impact. 
A significant difference was documented between the IMP explants and the UNIMP188 
(p < 0.05), IMP188 (p = 0.002), IMP188-4 (p = 0.033), and the IMP188-7 (p =0.015) 
Figure 9. Results for meniscal cell viability per treatment group, normalized 
to the UNIMP group. * denotes significant difference (p < 0.05) from the 
IMP treatment group. 
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explants. P188 did not affect cell viability when administered to the unimpacted explants. 
No depth dependent differences in cell viability were noted in any treatment groups.  
Histologically, there were no documented significant differences in GAG 
intensity (Figure 10) or GAG coverage (Figure 11) between any of the treatment groups.  
 
Figure 10. Results for GAG staining intensity in meniscal 
explants per treatment group.  
Figure 11. Results for percent GAG coverage in meniscal explants 
per treatment group. 
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Similarly, there were no documented significant differences in cell apoptosis 
levels between any of the treatment groups (Figure 12) for these samples at day 14.  
 
DISCUSSION 
  To the best of the authors’ knowledge, this is the first study to show data on the 
efficacy of P188 on cell viability for traumatized meniscal tissue, as well as the efficacy 
of multiple administrations of the surfactant. In the current study an impact of 50% strain 
produced significant cell death over the 14-day period.  Similar to previous studies in 
articular cartilage53,74,118,130,138, the current study documented that a single administration 
of P188 immediately following impact was effective in reducing cell death 14-days later. 
Some previous studies in articular cartilage suggest that giving the impacted tissues 
multiple administrations of the surfactant may result in a more effective treatment in 
preventing cell death and maintaining tissue integrity53,74,118. It has been reported that by 




sealing the cell membrane, P188 is able to counteract signaling pathways involved in the 
inflammatory response following impact, thus preventing cell death in articular 
cartilage9,118. The results of the current study were consistent with these studies in 
articular cartilage showing that P188 was able to prevent cell death in impacted knee 
joints.  However, no significant differences between single or multiple administrations of 
the surfactant were documented in the current study. This may suggest that at least for 
meniscal tissue, a single administration of P188 immediately following impact may be all 
that is necessary to prevent meniscal cell death. Sealing the cell membrane with P188 in 
meniscal cells may inhibit the release of mediators in the tissue following impact. Taken 
together, the findings of the current study suggest that a single dose of P188 immediately 
following impact may be all that is necessary to inhibit cell death in menisci. This 
inhibition of cell death following an impact load demonstrates that meniscal tissue is 
mechanically sensitive, which is consistent with previous studies.23-25, 36,42,44 
The findings on cell viability and cell apoptosis levels could suggest that necrosis 
from the physical stress of impact was likely the predominant cause of cell death in these 
menisci. However, no significant differences in apoptosis is not surprising given that 
apoptosis likely peaked earlier than day 14. Cells that undergo apoptosis-like cell death 
exhibit some of the signs associated with cells undergoing apoptosis, but they do not 
necessarily require caspase activity88. In articular cartilage, Garrido et al. reported that 7 
days after impact there was an increase in the rate of apoptosis, suggesting that 
immediate administration of P188 only delayed the onset of apoptosis rather than 
blocking it53.  The current study documented no significant differences in the levels of 
apoptosis between the six different treatment groups, albeit only evaluated at 14 days. It 
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should be noted that approximately 20-25% of cells are undergoing apoptosis in all 
groups. It is hypothesized that this is potentially due to the explants being in cell culture 
versus in vivo conditions.   
No significant changes in GAG content were documented between any of the 
treatment groups. Only one previous long-term study has assessed the efficacy of P188 in 
preserving GAG content in menisci. In a 6-week in vivo, post-traumatic injury animal 
model, Coatney et al. reported that a single intra-articular injection of P188 prevented 
significant GAG loss when compared to that of an impacted, untreated group29. It is 
unknown if the effect on GAG loss was direct or indirectly the result of injected P188. 
Fibrochondrocytes play a key role in meniscal function by producing the extracellular 
matrix that is responsible in maintaining the mechanical integrity of the tissue1,36,114. 
Previous studies have shown that musculoskeletal tissues subjected to a traumatic load 
release catabolic mediators, which contribute to the breakdown of the tissue 
matrix63,64,69,122,149. Furthermore, previous studies in lapine menisci have documented the 
decrease in GAG following an injurious impact over 8 and 12 week time points49. While 
there was a decrease in GAG coverage in the impacted limbs, compared to unimpacted 
controls, and P188 was able to keep GAG coverage levels the same as unimpacted 
controls, these changes were not significant. This may suggest that a 14-day post-
traumatic injury time point, as used in the current study, is perhaps too early to observe a 
significant difference in the long-term efficacy of P188 in preserving GAG content in 
menisci. It should also be noted that this study did remove the superficial zone and take 
samples from the outer region of the menisci in order to get a flat sample. Hence, these 
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results are primarily for the deep zone, which is where more glycosaminoglycans are 
present, compared to the superficial zone which is more interwoven collagen38. 
Only a few studies have documented the mechanosensitivity of meniscal tissue to 
impact loading. Kisiday et al., found that mechanical overloading resulted in significant 
increases in cell death in meniscal explants82. Hufeland et al., found a single injurious 
impact induced cell damage and release of GAG and reduced nitric oxide production and 
transcription of matrix-degrading enzymes 3 days post impact. Thus, this study 
contributes to the base knowledge of how meniscal tissue responds to injurious impact 
loads. Previous studies documented the behavior of meniscal tissue under normal loading 
conditions (10% strain) as well as conditions simulating partial meniscectomy (20% 
strain)59,104. These studies found proteoglycan breakdown, increases in cytokine-inducible 
nitric oxide synthase and interleukin-1 gene expression and increase in nitric oxide 
release to the surrounding media to occur at higher levels of strain. Studies have also 
shown that meniscal fibrochondrocytes are responsive to changes in shear stress44. These 
previous studies, along with the current study, demonstrate that the menisci are 
mechanically sensitive tissues. Thus, as the current study suggests, injurious impact loads 
likely ruptures cell membranes and the addition of P188 can maintain cell viability levels 
comparable to non-impacted meniscal tissue.      
The findings of the current study suggest that a single dose of P188 immediately 
following injury reduces the amount of cell death in the meniscus. A limitation of the 
current study includes qualitatively assessing changes in proteoglycan content. Future 
studies should also include quantitatively measuring the amount of GAGs in each sample 
to aid in determining if the treatment was successful in preventing changes in the 
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biochemical composition of the tissue. Similarly, changing the end point to later than the 
14-day period may show that there were changes in the qualitative changes (coverage and 
intensity scoring) of proteoglycans between the six different treatment groups. Exploring 
longer time points following impact may also help determine when P188 is no longer a 
viable option in preventing significant levels of cell death in tissues of the knee.  Cell 
necrosis levels have been shown to significantly increase 24 hours post-impact24,90, thus 
finding the ideal window to administer P188 will provide insight into the practicality of 
using the surfactant in a clinical setting.  
CONCLUSIONS 
A single, early dose of P188 was sufficient to inhibit cell death over 14 days in 
this in vitro study. This result may have direct implications in the potential administration 
of this surfactant in the clinical setting following anterior cruciate ligament rupture in 
order to save joint tissues from long term disease such as PTOA. Future studies, 
particularly in-vivo animal studies, will be needed to certainly recommend the use of 
P188. By addressing changes at the cellular level, pharmacological intervention paired 








ASSESSING MORPHOLOGICAL, FUNCTIONAL, AND HISTOLOGICAL 
CHANGES IN THE MENISCUS2 
 
INTRODUCTION 
Menisci are crescent shaped tissues found within the knee joint that aid in joint 
stability, load distribution and act to protect the underlying articular cartilage from large 
pressures during everyday loading.42,144 The mechanical properties of the tissue are 
largely contributed to the organization and composition of the solid matrix, which is 
mostly composed of collagen and proteoglycans (GAG).2,25,78 The collagen fibers found 
in the tissue are circumferentially oriented, which allow the menisci to convert the 
compressive forces it experiences from the femoral condyles into hoop stresses.5,129 
Proteoglycans are negatively charged proteins primarily found in the inner 2/3 of the 
tissue and aid in distributing compressive forces by attracting and retaining water in the 
tissue.2,78 Unfortunately, only the outer 1/3 of the tissue is vascularized, meaning damage 
and tears that occur within the inner 2/3 of the tissue are not able to heal properly.28,109  
Traumatic injuries to the knee joint often lead to damage to the anterior cruciate 
ligament (ACL) and menisci10–12. It has been long established that injuries to these soft 
tissues of the knee can induce post-traumatic osteoarthritis (PTOA)13–16, although the 
exact mechanisms to the onset of the disease remains unknown. Due to both the ACL and 
_______________________________________________________________________________________________________ 
2Portions of this chapter are adapted from a publication in the Journal of 
Biomechanics, Vol. 126, Narez GE, Brown G, Herrick A, Ek R, Wei F, Dejardin L, 
Haut RC, Haut Donahue TL, “Assessment of Changes in the Meniscus and 
Subchondral Bone in a Novel Closed-Joint Impact and Surgical Reconstruction 




meniscus being mostly avascular tissues, the most common treatment following damage 
include ACL reconstruction surgery and meniscal debridement for damage occurring in 
the avascular region of the meniscus. The goal of the surgery is to return normal knee 
kinematics and remove portions of the damaged tissue that could cause pain and 
discomfort to the patient. However, previous studies have shown that 78-83% of patients 
will develop PTOA 10-14 years post-injury, regardless of whether or not they receive 
surgical intervention following damage to the ACL and meniscus.46,131 It is believed that 
because surgical intervention fails to address any of the occult damage at the cellular 
level, which may play a crucial role in the onset of PTOA. Thus, pharmaceutical 
intervention that mitigates the progression of occult damage on the cellular level 
following a traumatic impact may be able to help mitigate further damage to the soft 
tissues within the knee joint and avert the progression of PTOA.  
Poloxamer 188 (P188) is a tri-block copolymer that has been shown to be an 
effective inhibitor of cell death in articular cartilage and meniscal tissue following 
traumatic impact.8,9,53,117,118,130 Both in-vivo and in-vitro studies using articular cartilage 
from the knee and ankle have found that a single 8mg/mL dose of the surfactant 
administered immediately following impact was able to significantly reduce cell death, 
compared to untreated samples.8,9,53,74,118,130,138 One study assessed the efficacy and 
multiple administrations of the surfactant in meniscal tissue and found that a single dose 
immediately following impact was all that was necessary to significantly reduce cell 
death in the tissue.117 Not only was P188 effective in preventing cell death, but by 
resealing compromised cell membranes following impact, P188 has also been shown to 
interfere with pathways associated with cell death and inflammation.9,148 All of these 
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findings suggest that P188 treatment may be able to address the occult damage following 
impact at the cellular level and merits further investigation in the in-vivo setting.  
The goal of the study was to assess if combined surgical and P188 treatment 
would be able to prevent or delay the onset of PTOA in meniscal tissue at three-time 
points (1, 3, and 6 months) compared to surgical treatment alone in an in-vivo lapine 
model that combined both closed-joint traumatic impact and surgical reconstruction. It 
was hypothesized that, compared to surgical intervention alone, combined treatment 
would be more effective in preventing degenerative changes associated with PTOA in the 
meniscus.  
METHODS 
Animal Model  
This study was approved by the Institutional Animal Care and Use Committee at 
Michigan State University. Ninety skeletally mature Flemish Giant rabbits (6.34 ± 0.75 
kg) aged 7 - 9 months were used for this study. Animals were a mix of male (n = 41) and 
female (n = 49). Animals were anesthetized (2% isoflurane and oxygen) and subjected to 
an impact of the right tibiofemoral joint until ACL failure and meniscal tissue damage. 
As previously described, the right knee of each rabbit was shaved and placed in a custom 
rigid fixture in a servo-hydraulic testing system (Instron Corp, Norwood, MA) while the 
rabbit was in a prone position (Figure 13).28,29 A 400 N preload was applied and a 
controlled impact pushed the tibia downward 3.5 mm at a rate of 0.5 Hz.30 The left knee 
served as a contralateral control.  
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Animals were then randomly assigned to one of four treatment groups; Group 1 
received reconstruction surgery only and no P188 treatment (Recon.), Group 2 received 
reconstruction surgery and a single dose of P188 immediately following impact (P188 
D0), Group 3 received reconstruction surgery and a dose of P188 immediately following 
impact and a second dose 24 hours after impact (P188 D1), and finally Group 4 received 
reconstruction surgery, a dose of P188 immediately following impact, a second dose 24 
hours following impact, and a third dose seven days after impact (P188 D7). For P188 
treatment groups, 1mL of P188 at a concentration of 8mg/mL was injected into the knee 
capsule at the respective time point. The knee joint was then flexed and extended to mix 
the P188 injection with the synovial fluid.  
Reconstruction of the torn ACL was performed by a board-certified veterinary 
surgeon (LD) approximately 2 weeks post-impact. A medial parapatellar arthrotomy was 
performed to assess the condition of the ACL and meniscus. Meniscal injuries, if present, 
were recorded and were treated via a partial, in which only the damaged or torn regions 
were removed, or full meniscectomy, in which the entire damaged medial or lateral 
meniscus was removed. The joint capsule was then opened and the semitendinosus (ST) 
Figure 13. Injurious impact of rabbit knee set-up. In prone position (belly down) 
the rabbit’s hind paw is supported directly below the actuator of an Instron and 




tendon was exposed on the posterior aspect of the medial tibial plateau. To minimize the 
amount of damage to the surrounding musculature, the ST tendon was then transected at 
the musculotendinous junction while leaving the tibial attachment intact. A 2.7 mm 
diameter tibial bone tunnel and a 3.2 mm diameter femoral tunnel were drilled at the 
ACL footprint. The free end of the ST graft was fed under the medial collateral ligament 
and then passed through the tunnels in the tibia and femur using a suture loop. Tension 
was applied on the graft and a custom interference fit screw was placed in the femoral 
bone tunnel to stabilize the graft.30,31 An anterior drawer test was performed on the 
reconstructed knee to ensure the joint was stable post-reconstruction.32 Animals were 
then euthanized at one of three time points 1-, 3-, and 6-months after the traumatic injury. 
The number of samples in each treatment group at each time point can be found in Table 
2. Following euthanasia, meniscal tissue was harvested for assessment of morphological, 
mechanical, and histological changes.  
Table 2. Number of samples per treatment group at each time point.  
Treatment Group 1 mo. 3 mo. 6 mo. 
Reconstruction Only (Recon) 6 6 6 
Reconstruction + P188 D0 (P188 D0) 8 8 8 
Reconstruction + P188 D0 &1 (P188 D1) 8 8 8 
Reconstruction + P188 D0, 1 &7 (P188 D1) 8 8 8 
 
Mechanical Analysis 
Indentation relaxation testing was conducted on the anterior, central and posterior 
regions of the menisci in a 1x PBS bath at room temperature using a servo-hydraulic 
testing system (MTS Corp, Eden Praire, MN) and a 9 N load cell (Futek, Irvine, CA). 
Following a 20mN pre-load, a 1.59-mm diameter steel indenter tip traveled to a depth of 
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0.25 mm and was held for 900 seconds to reach equilibrium. Similar to previous studies, 
Hertzian contact was assumed between an elastic half-space (meniscus) and a rigid 
sphere (indenter).28,29,33,34 A Poisson’s ratio of 0.01 was assigned to the tissue.35 The 
elastic modulus and Poisson’s ratio of the indenter were 210 GPa and 0.3 respectively. 
After testing, the tissue was fixed in 10% buffered formalin. A custom algorithm in 
MATLAB (Mathworks, Natick, MA) was used to calculate the instantaneous and 
equilibrium moduli from the data collected in the hydraulic testing system.  
Histological Analysis 
Tissue samples were immersed in a 30% sucrose solution for cryoprotection 
before being embedded in optimal cutting temperature (OCT) compound (Sakura, 
Finetek, Torrence, CA) and flash frozen in liquid nitrogen. The tissue samples were then 
sectioned to 6 μm and stained for glycosaminoglycan (GAG) content using hematoxylin, 
Safranin-O (Saf-O), and Fast Green (FG) staining. The slides were then imaged using a 
bright field microscope (Leica Microsystems Inc., Buffalo Grove, IL) and an Olympus 
DP25 camera (Olympus, Center Valley, PA). Staining intensity was graded similar to 
previous studies with no Saf-O staining represented by a score of 0, slight staining = 1, 
moderate staining = 2, and strong staining = 3 (Figure 14).33,36,37 Reported intensity 




GAG coverage was analyzed using ImageJ (NIH, Bethesda, MD) with the FIJI 
package.33,36 Briefly, total area of the section was calculated using the ‘Analyze 
Particles’ tool and summing particles. The area associated with GAG coverage (area 
stained red) was separated from the image using the ‘Colour Deconvolution’ tool. The 
percentage of GAG coverage was calculated as the total area of GAG coverage divided 
by the total area of the section multiplied by 100.   
Statistics 
To determine the influence of different treatments on the reconstructed limbs for 
the outcome measures (mechanical properties and GAG coverage), a mixed fixed effects 
model with repeated measures with Tukey’s post-hoc was applied with animal, time, and 
treatments as fixed effects. For both meniscal GAG staining intensity and morphology 
grading, a Mann-Whitney post-hoc on assigned-ranks was applied. Due to the amount of 
damage to the menisci of reconstructed limbs, not all regions had a sufficient sample size 
to perform regional analyses, hence all analyses were performed on average compartment 
data for each animal. A difference with p < 0.05 was considered statistically significant.   
Figure 14. Histological scoring of meniscus. (A) Strong staining is assigned a score of 
3, (B) moderate staining is assigned a score of 2, (C) slight staining is assigned a score 







The average peak impact load was 770 ± 137 N. During reconstructive surgery, 
the veterinarian surgeon (LD) documented that 50/90 experienced ACL rupture and 
40/90 experienced a partial ACL tear. Half of the animals had documented damage to the 
medial meniscus; 39/90 animals had tears in the posterior region, 4/90 had bucket handle 
tears, one animal had a small tear, and one animal had a discoid shape meniscus. In 
contrast, only four animals had documented damage to the lateral meniscus; three had 
tears in the posterior region and one had a bucket handle tear. Due to the initial damage, 
medial meniscectomies were more commonly performed; 40 animals received a partial 
medial meniscectomy and six received a full meniscectomy. Only four meniscectomies 
were performed on the lateral meniscus, three partial and one full. It was observed that 
the animals bore more weight on the contralateral control limb for 1-3 days following 
impact and 5-10 days following surgery before returning to normal gait. 
Morphological Analysis 
Statistically significant increases in damage between treated (right) and 
contralateral control (left) limbs were observed in both menisci (Table 3). At 1-month, in 
Table 3. Morphology grading for the meniscus. Values reported as Avg. ± Standard 
Deviation. * denotes statistical significant difference compared to control group at 
similar time point.  
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the lateral meniscus, P188 treated limbs saw a less significant increase in morphology 
grading, when compared to reconstruction surgery alone. However, P188 treatment did 
not seem to have the same effect at the later 3 and 6-month time points, as all treatment 
groups had a significant increase in damage, when compared to their respective control. 
In the medial meniscus, there was more severe damage found across all time-points in the 
treated limbs, regardless of treatment group.  
Mechanical Analysis  
Due to the excessive damage and degradation observed on the menisci of the 
reconstructed limbs, not all regions or tissue samples were able to be tested for changes in 
mechanical properties. Therefore, indentation results from the three regions (anterior, 
central, and posterior) of each menisci were averaged for each compartment and not all 
time points or treatment groups had similar sample sizes. Indentation-relaxation testing 
indicated that at the 1-month time point, all P188 treatments were effective in preventing 
a significant decrease in the instantaneous modulus of the lateral meniscus, compared to 
reconstruction only treatment. (Figure 15A.) At the later time points (3- and 6-months), 
multiple administrations of P188 were more effective in preventing further decreases in 
the modulus, compared to the Recon and P188 D0 groups. However, in the equilibrium 
Figure 15. Lateral meniscus mechanical property results. (A) Results for the 
instantaneous modulus (B) results for the equilibrium modulus. All values reported 
as Avg. ± Standard Error. * denotes statistical significant difference compared to 
control group at similar time point.  
 
53 
modulus of the lateral meniscus, it was documented that no treatment group, at any time 
point, was able to prevent a decrease in the modulus compared to their respective control 
(Figure 15B). 
In the medial meniscus, multiple doses of P188 (P188 D1 and P188 D7) were 
more consistent in preventing a significant decrease in the instantaneous modulus 
compared to control limbs, specifically at the later time 3- and 6-month time points. 
(Figure 16A). Similar results were observed in the equilibrium modulus of the tissue, 
where the multiple doses of P188 groups (P188D1 and P188 D7) were more effective in 
preventing a significant decrease in the modulus at the 3- and 6-month time points 
(Figure 16B).  
Histological Analysis 
Qualitatively assessing GAG staining intensity of the lateral meniscus found that 
at 1-month, there were only significant decreases in the P188 D0 and P188 D1 groups, 
compared to controls. (Figure 17A) At the 6-month time point, the only documented 
decrease was found in the Recon only group. At 3- and 6-months, all P188 treatment 
groups were able to prevent significant decreases in staining intensity in the lateral 
Figure 16. Medial meniscus mechanical property results. (A) Results for the 
instantaneous modulus (B) results for the equilibrium modulus. All values reported 
as Avg. ± Standard Error. * denotes statistical significant difference compared to 
control group at similar time point.  
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meniscus compared to controls. In the medial meniscus, the only significant difference 
found was a decrease in staining intensity in the P188 D1 group. (Figure 17B).   
Quantitatively assessing GAG coverage of the lateral meniscus found that at the 
1-month time points, all P188 treatment groups had a significant decrease in coverage 
compared to control groups. There was no significant decrease in the Recon group at this 
time point. However, at the 3-month time point, there was a significant decrease in the 
Recon group, but all P188 treatment groups were able to prevent a significant decrease 
compared to controls. (Figure 18A). In the medial meniscus, there was only a significant 
decrease in GAG coverage found in the 1-month Recon group. (Figure 18B).  
Figure 18. GAG coverage results for both menisci. (A) Results for the lateral 
meniscus (B) results for the medial meniscus. All values reported as Avg. ± Standard 
Error. * denotes statistical significant difference compared to control group at 
similar time point.  
Figure 17. GAG intensity results for both menisci. (A) Results for the lateral 
meniscus (B) results for the medial meniscus. All values reported as Avg. ± Standard 
Error. * denotes statistical significant difference compared to control group at 




This animal model was successful in simulating acute knee joint damage by 
creating rupture or damage to the ACL and menisci. The observed damage to the menisci 
was more commonly found in the medial meniscus compared to the lateral meniscus, 
therefore medial meniscectomies were more commonly performed. These observations 
match observed clinical results in humans who have suffered traumatic injuries to the 
knee and received surgical intervention, further highlighting the clinical relevance of this 
model. Changes documented in the mechanical properties and GAG staining of the 
meniscus in the Recon group match signs of PTOA found in humans as well. Some of 
these changes were documented as early as 1-month following the traumatic impact. 
Although not always consistent, this study found that both single and multiple 
administrations of P188 were able to limit changes in mechanical properties and GAG 
staining associated with the disease, when compared to reconstruction treatment alone, 
especially at later time points.  
Previous in-vivo lapine studies have utilized a similar closed-joint traumatic 
impact injury model to induce ACL failure and meniscal damage without surgical 
intervention to repair the ACL and treat damaged menisci. These previous studies 
reported significant changes in morphology grading, mechanical properties, and GAG 
staining of both menisci, but only at later time points (8 and 12 weeks).48,49 In contrast, 
the earlier differences documented in the current study could be attributed to the partial or 
full meniscectomies performed during reconstruction surgery, since this surgical 
procedure has been documented to cause a change in loading patterns within the 
joint.151,155,160 Compared to the previous studies with no reconstruction, at the 3-month 
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time point (12 weeks), it appears that surgical intervention was able to limit the amount 
of degradation in the mechanical properties and loss of proteoglycans in the meniscus. 
The effect of surgical intervention aiding in limiting the amount of degradation in the 
meniscus is further supported by the current study, since the amount of total degradation 
found at 6-months was not as severe as in the two previous studies, although the previous 
studies did not include such a long time point.  
 
In the current study, morphological assessments of the meniscus before and after 
surgical intervention showed more damage to the medial meniscus than the lateral 
meniscus, with the severity of damage increasing over time, regardless of which 
treatment group animals were in. These changes could be attributed to the meniscectomy 
performed on the tissue during reconstruction surgery, as medial meniscectomies were 
more commonly performed and this procedure involves removing portions of the tissue, 
affecting its gross appearance. Morphological grading of the lateral meniscus at the 1-
month time point suggested that P188 treatment was able to help limit degenerative 
changes in the tissue, since only the Recon group had an increase in tissue degeneration. 
A previous study by Bajaj et al., in which the mechanisms of P188 on cellular signaling 
were explored, documented that the surfactant was able to inhibit the Stat1 and Stat3 
pathways, which are associated with the down regulation of collagen and ultimately 
impairs matrix formation.23,41 By preventing the down regulation of collagen, a single 
or multiple treatments of P188 may have been able to prevent further degradation of the 




P188 treatment may have been effective in preventing damage to the lateral 
menisci at an early time point, but perhaps a shift in load distribution within the joints of 
the animals caused an increase in damage as noted in the morphology grading of the 
tissue, especially at later time points. At the 3- and 6-month time points, there were 
degenerative changes documented in the lateral meniscus of all treatment groups. These 
changes could be attributed to the meniscectomy performed on the medial meniscus. As 
previously mentioned, it has been reported that meniscectomies cause changes in joint 
loading, which could shift larger amounts of load onto the lateral meniscus and ultimately 
lead to the greater amount of damage observed.151,155,160  
 A single and multiple administrations of P188 were more consistent in 
maintaining the instantaneous modulus of the lateral meniscus comparable to that of the 
control limbs across all three time points. A similar trend was observed in the medial 
meniscus, but only at the later 3- and 6-month time points. Previous studies have 
proposed that, under compression, the instantaneous modulus of the tissue is related to 
the water content and permeability, and the equilibrium modulus is related to the solid 
matrix, primarily GAG content.11,110,132,140,161 As previously mentioned, P188 treatment 
has been shown to inhibit pathways associated with the down regulation of collagen 
production, which could explain the lack of changes documented in the lateral meniscus 
across all time points and in the medial meniscus at later time points. Within the solid 
matrix, collagen helps prevent the secretion of water out of the tissue by creating drag 
forces, thus aiding in supporting large loads immediately following compression.25   
Although P188 treatment seemed to have helped prevent changes in the 
instantaneous modulus of the tissue, the current study found no benefit of P188 treatment 
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in preventing changes in the equilibrium modulus. Both the lateral and medial meniscus 
experienced a decrease in the equilibrium modulus at 1-month, regardless of treatment 
group. At this time point, a decrease in the modulus of the P188 treated groups was 
accompanied by a decrease in both GAG coverage and staining intensity, which supports 
the understanding of the relationship between GAG content and the mechanical 
properties of the tissue at equilibrium. The observed decrease in modulus of the tissue in 
the Recon group could be associated with possible changes in collagen content within the 
solid matrix, which could explain the decreases in the equilibrium modulus, but lack of 
changes in GAG content. Interestingly, at later time points, a decrease in the equilibrium 
modulus was only consistently documented in both menisci of the Recon groups. These 
decreases were accompanied with decreases in GAG coverage and staining intensity.  
In the P188 treated limbs, decreases of the equilibrium modulus were more 
commonly documented in the lateral meniscus, compared to the medial meniscus. Unlike 
at the 1-month time point, these changes were not accompanied with a decrease in GAG 
coverage or staining intensity. As it has been documented that either single or multiple 
treatments of P188 are able to prevent cell death following a traumatic impact in the 
meniscus, perhaps the mechanism by increasing cell viability the fibrochondrocytes in the 
meniscus were able to upregulate the production of proteoglycans over time.117 A 
previous in-vivo study by Coatney et al. testing the efficacy of P188 in preventing 
proteoglycan loss in the meniscus using a constrained joint impact model reported that 6-
weeks following treatment, a single dose of P188 was able to significantly prevent the 
loss of GAGs compared to the untreated impact group29, matching the findings of the 
current study in the P188 treatment groups.  
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There were a number of limitations in the current study including reduced sample 
size of meniscal tissue for mechanical testing in the treated limbs. Due to the amount of 
damage documented in the tissues, particularly the medial meniscus, not all groups had a 
full sample size based on the total number of animals enrolled in the study. Future studies 
should anticipate severe damage to the meniscus as a result of the impact and should 
include a larger sample size. To test if P188 treatments were able to limit the down 
regulation of collagen within the tissue, future studies should conduct tensile testing as 
well as investigate collagen content through histological, biochemical, or other imaging 
analysis. Since the current study documented somewhat inconsistent longitudinal changes 
associated with PTOA between the three P188 treatment groups, future studies may want 
to include much later time points to assess the effect of the different treatments over a 
longer period of time. 
CONCLUSIONS 
        This is the first study to assess changes in the menisci following combined P188 and 
surgical treatment. The current study suggests that P188 treatment and subsequent 
surgical intervention may be effective in limiting changes associated with PTOA in the 
meniscus, when compared to reconstruction only treatments. However, in order to fully 
prevent changes associated with the disease, alternative treatments that address the 
damage and tears from the initial impact may be necessary, such as a full meniscal 








EVALUATING CHRONIC CHANGES IN SUBCHONDRAL CORTICAL AND 
TRABECULAR BONE OF FEMURS AND TIBIAS2  
 
INTRODUCTION 
 Subchondral bone plays a critical role within the knee joint by providing 
mechanical support and nutrition to the articular cartilage.97 This region of bone consists 
of both nonporous cortical bone and spongy trabecular bone that undergo constant 
adaptation, through resorption and remodeling, in response to changes in the mechanical 
loading the knee experiences from every day activities.20,101,159 Under normal 
physiological conditions, the amount of bone removed during the resorption phase is 
balanced by the amount of bone that is made during the formation phase. Through this 
process, bone mass is maintained, although the shape and architecture of bone is 
modified to repair micro-damage resulting from external loading.56,159 
 Traumatic injuries to the knee joint often lead to damage to the anterior cruciate 
ligament (ACL) and menisci35,93,120 and are known to induce biological responses in the 
bone and soft tissues of the joint, which are strongly associated with the onset of post-
traumatic osteoarthritis (PTOA).44,62,98,119 Following a traumatic injury and ACL rupture, 
subchondral bone remodels resulting in changes to trabecular bone architecture, loss of 
mineral density, formation of osteophytes, and the advancement of the tidemark, which 
_______________________________________________________________________________________________________ 
2Portions of this chapter are adapted from a publication in the Journal of 
Biomechanics, Vol. 126, Narez GE, Brown G, Herrick A, Ek R, Wei F, Dejardin L, 
Haut RC, Haut Donahue TL, “Assessment of Changes in the Meniscus and 
Subchondral Bone in a Novel Closed-Joint Impact and Surgical Reconstruction 




causes a decrease in articular cartilage thickness.14,19,57,105,170 These changes are amplified 
with the onset and progression of the disease.  
The most common treatment following injury to the ACL and meniscus includes 
ACL reconstructive surgery and meniscal debridement. The goal of treatment is to return 
normal kinematics to the joint and decrease pain by removing damaged and torn pieces of 
tissue. While the surgery alleviates pain and returns some normal knee kinematics, 
patients still develop PTOA 10-14 years post injury.46,50,115,131 It is believed that occult 
damage at the cellular level that is caused by the initial impact, which is not addressed 
during surgical intervention, may play a crucial role in the onset of the disease. Thus, 
pharmaceutical intervention that addresses and mitigates cellular damage following 
traumatic impact may be able to prevent further damage to the tissues within the knee 
joint and avert the progression of PTOA following ACL reconstruction surgery.  
In recent years, Poloxamer 188 (P188) has become a surfactant of interest as it 
has been shown that a single 8mg/mL dose is an effective inhibitor of cell death in 
articular cartilage and meniscal tissue following traumatic impact.8,9,53,117,118,130 A 
previous study by Bajaj et al. reported that P188 treatment was able to inhibit pathways 
associated with cell death, inflammation, and matrix degradation in articular cartilage 
explants.9  These findings suggest that P188 treatment may be able to arrest the occult 
damage following impact at the cellular level and merits further investigation in the in-
vivo setting. To the author’s knowledge, no previous studies have tested the efficacy of 
the surfactant on bone tissue following an injurious joint impact.  
The goal of the study was to assess if combined surgical and intra-articular P188 
treatment would be able to prevent or delay the longitudinal development of PTOA in 
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meniscal tissue compared to surgical treatment alone in an in-vivo lapine model that 
combined both closed-joint traumatic impact and surgical reconstruction. It was 
hypothesized that, compared to surgical treatment alone, combine treatment would be 
more effective in preventing degenerative changes associated with PTOA in the 
subchondral bone.  
METHODS 
Animal Model  
This study was approved by the Institutional Animal Care and Use Committee at 
Michigan State University. Ninety skeletally mature Flemish Giant rabbits (6.34 ± 0.75 
kg) aged 7 - 9 months were used for this study. Animals were a mix of male (n = 41) and 
female (n = 49). Animals were anesthetized (2% isoflurane and oxygen) and the right 
tibiofemoral joint was subjected to an impact resulting in ACL failure and meniscal tissue 
damage. As previously described, the right knee of each rabbit was shaved and placed in 
a custom rigid fixture in a servo-hydraulic testing system (Instron Corp, Norwood, MA) 
while the rabbit was in a prone position (Figure 13).28,29 A 400 N preload was applied 
and a controlled impact pushed the tibia downward 3.5 mm at a rate of 0.5 Hz.30 The left 
knee served as a contralateral control.  
Animals were then randomly assigned to one of four treatment groups; Group 1 
received reconstruction surgery only and no P188 treatment (Recon.), Group 2 received 
reconstruction surgery and a single dose of P188 immediately following impact (P188 
D0), Group 3 received reconstruction surgery and a dose of P188 immediately following 
impact and 24 hours after impact (P188 D1), and finally Group 4 received reconstruction 
surgery and a dose of P188 immediately following impact, 24 hours, and seven days after 
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impact (P188 D7). For P188 treatment groups, 1mL of P188 at a concentration of 
8mg/mL was injected into the knee capsule at the respective time point. The knee joint 
was then flexed and extended to mix the P188 injection with the synovial fluid.  
Reconstruction of the torn ACL was performed by a board-certified veterinary 
surgeon (LD) approximately 2 weeks post-impact. A medial parapatellar arthrotomy was 
performed to assess the condition of the ACL and meniscus. Meniscal injuries, if present, 
were recorded and were treated via a partial, in which only the damaged or torn regions 
were removed, or full meniscectomy, in which the entire damaged medial or lateral 
meniscus was removed. The joint capsule was then opened and the semitendinosus (ST) 
tendon was exposed on the posterior aspect of the medial tibial plateau. To minimize the 
amount of damage to the surrounding musculature, the ST tendon was then transected at 
the musculotendinous junction while leaving the tibial attachment intact. A 2.7 mm 
diameter tibial bone tunnel and a 3.2 mm diameter femoral tunnel were drilled at the 
ACL footprint. The free end of the ST graft was fed under the medial collateral ligament 
and then passed through the tunnels in the tibia and femur using a suture loop. Tension 
was applied on the graft and a custom interference fit screw was placed in the femoral 
bone tunnel to stabilize the graft.30,31 An anterior drawer test was performed on the 
reconstructed knee to ensure the joint was stable post-reconstruction.32 Following 
mechanical testing on the articular cartilage of the femurs and tibias by the collaborating 
lab at Michigan State University, both bones were fixed in 10% neutral buffered formalin 
for further analysis. The number of animals included in each treatment group at 
euthanized at 1-, 3-, or 6-months following impact can be found in Table 2. 
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Micro - Computed Tomography (μCT) 
The distal femur and proximal tibia from both the contralateral control (left) and 
treated (right) limbs from each animal were scanned in 10% neutral buffered formalin 
using a Bruker Skyscan 1276 (Bruker, Billerica, MA) μCT machine. Bones were scanned 
with a voxel size of 20 µm and a 1mm aluminum and copper filter. The x-ray tube 
parameters were a voltage of 100 kV, current of 125 µA, and exposure time of 473 ms. 
Images were collected every 0.4º using a 360º rotation around the sample.  
Three-dimensional image reconstructions were performed using NRecon software 
(Bruker, Billerica, MA). All reconstructions were performed using a dynamic range of 0 
to 0.030, universal beam hardening of 30%, Gaussian smoothing of 3, and a ring artifact 
correction of 4.  Misalignment compensations varied between each reconstruction image 
set to ensure images were of the highest quality. Reconstructed images were then 
imported to DataViewer software (Bruker, Billerica, MA) to isolate the volume of 
interest (VOIs) for each type of bone being analyzed. Trabecular VOIs ranged from just 
below the cortical bone to growth plate. Cortical bone VOIs ranged from the joint margin 
to the trabecular bone.   
CTAn software (Bruker, Billerica, MA) was used for all quantitative bone 
analysis. Similar to previous studies, four regions of interest (ROI) were chosen to 
coincide with areas of mechanical testing on the articular cartilage of the lateral and 




Parameters of interest for subchondral bone include bone mineral density 
(Tb.BMD), bone volume/tissue volume (BV/TV), trabecular number (Tb.N), trabecular 
thickness (Tb.Th), and trabecular separation (Tb.Sp). Parameters of interest for cortical 
bone include bone mineral density (Co.BMD), porosity (Co.Po), and cortical thickness 
(Co.Th). Using CTAn software, osteophytes were identified by manually outlining new 
bone growth outside of the normal joint margins every 20 slides by a single operator and 
morphing the images together. Osteophytic bone volume was identified by reduced bone 
mineral density and as being outside the original joint margins (Figure 20). 
 
Figure 20. Representative image of a tibia with new osteophytic bone being outlined 
(bone in red area). 
Figure 19.  Representative images of mechanical testing locations 
on both tibias and femurs and the corresponding locations on the 




To determine the influence of different treatments on the reconstructed limbs on 
the analyzed variables (subchondral bone morphometry, mineral composition, and 
osteophyte volume), a mixed fixed effects model with repeated measures with Tukey’s 
post-hoc was applied with animal, time, and treatments as fixed effects. All comparisons 
made were between the treated limbs and contralateral control limbs for each treatment 
group, except for osteophyte volume, in which comparisons were made for the femurs 
and tibias between treatment groups at each time point due to no osteophyte volume 
being documented in control limbs. A difference with p < 0.05 was considered 
statistically significant.  
RESULTS 
Animal Model 
The average peak impact load was 770 ± 137 N. During reconstructive surgery, 
the veterinarian surgeon (LD) documented that 50/90 experienced ACL rupture and 
40/90 experienced a partial ACL tear. Half of the animals had documented damage to the 
medial meniscus; 39/90 animals had tears in the posterior region, 4/90 had bucket handle 
tears, one animal had a small tear, and one animal had a discoid shape meniscus. In 
contrast, only four animals had documented damage to the lateral meniscus; three had 
tears in the posterior region and one had a bucket handle tear. Due to the initial damage, 
medial meniscectomies were more commonly performed; 36 animals received a partial 
medial meniscectomy, six received a full meniscectomy, and four received a posterior 
horn release meniscectomy. Only four meniscectomies were performed on the lateral 
meniscus, three partial and one full. It was observed that the animals favored the 
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contralateral control limb for 1-3 days following impact and 5-10 days following surgery 
before returning to normal gait. 
Trabecular Bone 
When compared to contralateral control limbs, the lateral (Figure 21A) and 
medial (Figure 21B) condyles of the Recon group had an 11% and 16% decrease, 
respectively, in mineral density at 3-months. At 6-months, there was a 10% decrease in 
the medial condyle in the P188 D1 group (Figure 21B). At this time point, in the lateral 
compartments of tibias, there was a 12% decrease in mineral density in the Recon group 
and a 13% decrease in the P188 D7 group (Figure 21C). There were no significant 
decreases found in the medial plateau in any treatment group (Figure 21D). 
 
Figure 21. Bone mineral density (BMD) measurements for the trabecular bone of 
(A) lateral and (B) femoral condyles as well as the (C) lateral and (D) medial 
compartments of the tibia. Values reported as average ± standard error. * denotes 
significant difference between treated (right) limb to respective control (left) limbs. 
 
Analyses of trabecular BV/TV documented no changes in the lateral condyle of 
the femurs in any treatment group (Figure 22A), but there was a 19% decrease in the 
 
68 
medial condyle in the P188 D7 group at 6-months (Figure 22B). In the tibias, there were 
documented decreases in BV/TV in the lateral compartment in the Recon group at 3- and 
6-months (Figure 22C). At 3-months, there was a 36% decrease in the lateral 
compartment in the P188 D0 group (Figure 22C). There were no documented changes in 
the medial plateau in any treatment group (Figure 22D).  
 
Figure 22. Bone volume tissue volume (BV/TV) measurements for the trabecular 
bone of (A) lateral and (B) femoral condyles as well as the (C) lateral and (D) medial 
compartments of the tibia. Values reported as average ± standard error.  * denotes 
significant difference between treated (right) limb to respective control (left) limbs. 
 
Bone morphometry analyses found more significant changes in the lateral 
condyles than the medial condyles of the femurs (Table 4). In the P188 D1 group, there 
was a 25% increase in Tb.N in the lateral condyles at 1-month and a 19% decrease in 
Tb.Th at 3-months. Both condyles in the P188 D0 group had an increase in Tb.Sp at 3-




Table 4. Measured trabecular bone parameters for each condyle of the femur. 
Values reported as average ± standard deviation.  * denotes significant difference 
between treated (right) limb to respective control (left) limbs. 
 
      Lateral Medial 
      Tb.N (mm-1) Tb.Th (mm) Tb.Sp (mm-1) Tb.N (mm-1) Tb.Th (mm) Tb.Sp (mm-1) 
1 mo. 
Recon  
Control 1.70 ± 0.44 0.24 ± 0.03 0.41 ± 0.09 1.62 ± 0.40 0.24 ± 0.01 0.42 ± 0.08 
Treated 1.74 ± 0.46 0.24 ± 0.02 0.39 ± 0.14 1.44 ± 0.44 0.25 ± 0.04 0.47 ± 0.12 
P188 D0 
Control 1.70 ± 0.36 0.21 ± 0.04 0.41 ± 0.09 1.44 ± 0.33 0.28 ± 0.19 0.46 ± 0.09 
Treated 1.86 ± 0.10 0.21 ± 0.04 0.34 ± 0.05 1.55 ± 0.3 0.22 ± 0.03 0.42 ± 0.06 
P188 D1  
Control 1.55 ± 0.36 0.18 ± 0.02 0.45 ± 0.07 1.86 ± 0.54 0.20 ± 0.04 0.38 ± 0.14 
Treated 1.93 ± 0.22* 0.17 ± 0.02 0.35 ± 0.06 1.68 ± 0.14 0.18 ± 0.03 0.37 ± 0.10 
P188 D7 
Control 2.02 ± 0.45 0.18 ± 0.03 0.37 ± 0.12 1.94 ± 0.27 0.21 ± 0.02 0.36 ± 0.06 
Treated 2.10 ± 0.34 0.20 ± 0.01 0.33 ± 0.08 1.96 ± 0.23 0.19 ± 0.01 0.37 ± 0.06 
3 mo. 
Recon  
Control 1.77 ± 0.4 0.23 ± 0.04 0.42 ± 0.16 1.61 ± 0.44 0.27 ± 0.04 0.43 ± 0.12 
Treated 2.04 ± 0.27 0.22 ± 0.04 0.31 ± 0.06 1.71 ± 0.25 0.21 ± 0.03 0.36 ± 0.10 
P188 D0 
Control 1.53 ± 0.35 0.21 ± 0.05 0.41 ± 0.06 1.55 ± 0.34 0.21 ± 0.04 0.43 ± 0.06 
Treated 1.52 ± 0.36 0.22 ± 0.04 0.43 ± 0.09* 1.30 ± 0.33 0.20 ± 0.02 0.55 ± 0.16* 
P188 D1  
Control 1.83 ± 0.16 0.25 ± 0.05 0.37 ± 0.07 2.04 ± 0.23 0.24 ± 0.02 0.35 ± 0.07 
Treated 1.86 ± 0.21 0.20 ± 0.02* 0.38 ± 0.05 1.92 ± 0.13 0.24 ± 0.04 0.35 ± 0.02 
P188 D7 
Control 1.86 ± 0.27 0.19 ± 0.03 0.42 ± 0.11 1.89 ± 0.33 0.22 ± 0.02 0.39 ± 0.09 
Treated 1.85 ± 0.19 0.20 ± 0.02 0.38 ± 0.04 1.83 ± 0.17 0.23 ± 0.06 0.37 ± 0.04 
6 mo.  
Recon  
Control 1.57 ± 0.25 0.26 ± 0.04 0.44 ± 0.07 1.72 ± 0.24 0.24 ± 0.02 0.39 ± 0.03 
Treated 1.86 ± 0.43 0.25 ± 0.08 0.36 ± 0.07 1.62 ± 0.47 0.23 ± 0.05 0.45 ± 0.10 
P188 D0 
Control 1.60 ± 0.12 0.19 ± 0.02 0.45 ± 0.08 1.79 ± 0.42 0.19 ± 0.01 0.40 ± 0.09 
Treated 1.85 ± 0.18 0.19 ± 0.03 0.36 ± 0.03 1.65 ± 0.26 0.19 ± 0.02 0.42 ± 0.08 
P188 D1  
Control 1.87 ± 0.14 0.18 ± 0.03 0.39 ± 0.04 1.92 ± 0.22 0.21 ± 0.03 0.35 ± 0.05 
Treated 1.90 ± 0.3 0.19 ± 0.02 0.37 ± 0.07 1.93 ± 0.24 0.18 ± 0.01 0.37 ± 0.05 
P188 D7 
Control 1.82 ± 0.19 0.20 ± 0.03 0.40 ± 0.02 1.88 ± 0.20 0.23 ± 0.01 0.35 ± 0.03 
Treated 1.81 ± 0.28 0.21 ± 0.03 0.40 ± 0.07 1.80 ± 0.21 0.19 ± 0.03 0.38 ± 0.06 
 
 
The only morphometry change documented in the tibias was a 19% increase in 
Tb.Th in the medial compartment in the P188 D1 group at 6-months. There were no 







Table 5. Measured trabecular bone parameters for each compartment of the tibia. 
Values reported as average ± standard deviation.  * denotes significant difference 
between treated (right) limb to respective control (left) limbs. 
 
   
Lateral Medial 
      Tb.N (mm
-1) Tb.Th (mm) Tb.Sp (mm-1) Tb.N (mm-1) Tb.Th (mm) Tb.Sp (mm-1) 
1 mo. 
Recon  
Control 1.75 ± 0.35 0.26 ± 0.04 0.40 ± 0.08 1.35 ± 0.19 0.33 ± 0.06 0.45 ± 0.1 
Treated 1.62 ± 0.27 0.26 ± 0.04 0.39 ± 0.06 1.77 ± 0.51 0.27 ± 0.06 0.40 ± 0.13 
P188 D0 
Control 1.77 ± 0.56 0.22 ± 0.05 0.41 ± 0.13 1.74 ± 0.2 0.26 ± 0.05 0.39 ± 0.08 
Treated 1.81 ± 0.31 0.22 ± 0.03 0.38 ± 0.08 1.67 ± 0.41 0.22 ± 0.05 0.43 ± 0.13 
P188 D1  
Control 1.96 ± 0.37 0.24 ± 0.04 0.33 ± 0.07 1.76 ± 0.43 0.27 ± 0.05 0.42 ± 0.12 
Treated 1.81 ± 0.48 0.24 ± 0.06 0.39 ± 0.1 1.86 ± 0.29 0.28 ± 0.07 0.35 ± 0.08 
P188 D7 
Control 1.99 ± 0.21 0.24 ± 0.03 0.33 ± 0.05 1.81 ± 0.22 0.22 ± 0.04 0.39 ± 0.04 
Treated 2.14 ± 0.37 0.24 ± 0.04 0.32 ± 0.08 1.97 ± 0.21 0.26 ± 0.04 0.33 ± 0.06 
3 mo. 
Recon  
Control 1.71 ± 0.44 0.28 ± 0.05 0.40 ± 0.09 1.62 ± 0.23 0.29 ± 0.03 0.39 ± 0.05 
Treated 1.49 ± 0.52 0.24 ± 0.05 0.43 ± 0.13 1.42 ± 0.43 0.25 ± 0.07 0.43 ± 0.15 
P188 D0 
Control 1.98 ± 0.32 0.25 ± 0.03 0.35 ± 0.05 1.76 ± 0.45 0.27 ± 0.03 0.40 ± 0.09 
Treated 1.65 ± 0.41 0.18 ± 0.02 0.41 ± 0.09 1.71 ± 0.35 0.26 ± 0.09 0.40 ± 0.14 
P188 D1  
Control 1.80 ± 0.27 0.26 ± 0.02 0.38 ± 0.06 1.61 ± 0.21 0.29 ± 0.07 0.43 ± 0.05 
Treated 1.71 ± 0.46 0.23 ± 0.02 0.40 ± 0.07 1.75 ± 0.16 0.27 ± 0.11 0.35 ± 0.08 
P188 D7 
Control 1.85 ± 0.26 0.25 ± 0.02 0.36 ± 0.12 1.8 ± 0.14 0.28 ± 0.02 0.37 ± 0.05 
Treated 1.76 ± 0.49 0.20 ± 0.03 0.41 ± 0.12 1.7 ± 0.39 0.26 ± 0.05 0.37 ± 0.09 
6 mo.  
Recon  
Control 1.77 ± 0.4 0.28 ± 0.05 0.39 ± 0.09 1.35 ± 0.48 0.33 ± 0.09 0.51 ± 0.18 
Treated 1.48 ± 0.41 0.27 ± 0.06 0.46 ± 0.14 1.83 ± 0.33 0.24 ± 0.05 0.36 ± 0.11 
P188 D0 
Control 1.5 ± 0.37 0.27 ± 0.09 0.47 ± 0.16 1.72 ± 0.54 0.23 ± 0.03 0.39 ± 0.09 
Treated 1.67 ± 0.18 0.22 ± 0.03 0.43 ± 0.04 1.68 ± 0.26 0.24 ± 0.05 0.41 ± 0.04 
P188 D1  
Control 2.18 ± 0.21 0.28 ± 0.04 0.30 ± 0.02 1.97 ± 0.26 0.29 ± 0.05 0.34 ± 0.09 
Treated 1.93 ± 0.38 0.21 ± 0.05 0.33 ± 0.04 1.9 ± 0.35 0.34 ± 0.14* 0.33 ± 0.09 
P188 D7 
Control 2.05 ± 0.17 0.23 ± 0.04 0.34 ± 0.05 1.99 ± 0.25 0.29 ± 0.06 0.35 ± 0.07 







 There were no documented changes in cortical BMD in either the lateral 
(Figure 23A) or medial (Figure 23B) femoral condyle. Similarly, there were no 
documented changes in cortical BMD in either the lateral (Figure 23C) or medial (Figure 
23D) compartments of the tibia in any of the treatment groups at any time.  
 
Table 23. Bone mineral density (BMD) measurements for the cortical bone of (A) 
lateral and (B) femoral condyles as well as the (C) lateral and (D) medial 
compartments of the tibia. Values reported as average ± standard error.  * denotes 
significant difference between treated (right) limb to respective control (left) limbs. 
 
Analyzing cortical bone porosity and thickness of the femurs found an increase in 
both parameters in the lateral condyle of the Recon group at 1-month. At 3-months, there 
was an increase in porosity in the P188 D0 group and a decrease in thickness in the P188 
D1 group (Table 6). There was an increase in cortical thickness in the P188 D7 group at 
6-months. In the medial condyle, only an increase in cortical thickness was found in the 
Recon group at 1-month.  
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Table 6. Measured cortical bone parameters for each condyle of the femur. Values 
reported as average ± standard deviation. * denotes significant difference between 
treated (right) limb to respective control (left) limbs. 
 
      Lateral Medial 
      Co.Po (%) Co.Th (mm) Co.Po (%) Co.Th (mm) 
1 mo. 
Recon  
Control 5.93 ± 2.04 0.57 ± 0.07 6.7 ± 3.89 0.60 ± 0.12 
Treated 8.59 ± 4.5* 0.67 ± 0.13* 7.95 ± 2.42 0.59 ± 0.04 
P188 D0 
Control 3.53 ± 1.63 0.59 ± 0.05 2.64 ± 1.19 0.56 ± 0.08 
Treated 3.36 ± 1.98 0.61 ± 0.09 2.93 ± 2.11 0.61 ± 0.10 
P188 D1  
Control 2.13 ± 1.25 0.6 ± 0.09 2.08 ± 1.71 0.66 ± 0.02 
Treated 4.36 ± 3.48 0.51 ± 0.09 1.51 ± 1.05 0.57 ± 0.10 
P188 D7 
Control 2.58 ± 1.32 0.71 ± 0.06 1.8 ± 1.19 0.71 ± 0.10 
Treated 5.19 ± 3.2 0.67 ± 0.11 3.4 ± 2.14 0.73 ± 0.09 
3 mo. 
Recon  
Control 10.29 ± 3.22 0.51 ± 0.06 7.60 ± 2.02 0.58 ± 0.13 
Treated 8.23 ± 2.39 0.62 ± 0.10 7.31 ± 1.76 0.68 ± 0.12* 
P188 D0 
Control 2.05 ± 1.00 0.60 ± 0.05 2.84 ± 2.26 0.62 ± 0.12 
Treated 6.17 ± 5.81* 0.52 ± 0.15 3.13 ± 1.19 0.58 ± 0.05 
P188 D1  
Control 3.81 ± 0.71 0.71 ± 0.13 4.74 ± 1.28 0.76 ± 0.09 
Treated 3.25 ± 0.98 0.53 ± 0.06* 3.40 ± 1.45 0.79 ± 0.16 
P188 D7 
Control 4.82 ± 3.52 0.71 ± 0.08 3.33 ± 1.05 0.74 ± 0.15 
Treated 4.07 ± 2.07 0.59 ± 0.05 4.63 ± 0.90 0.75 ± 0.08 
6 mo.  
Recon  
Control 8.97 ± 2.31 0.57 ± 0.13 7.96 ± 1.68 0.62 ± 0.11 
Treated 7.36 ± 1.65 0.57 ± 0.08 7.43 ± 4.92 0.61 ± 0.09 
P188 D0 
Control 3.55 ± 2.62 0.69 ± 0.12 4.27 ± 2.68 0.70 ± 0.07 
Treated 5.29 ± 3.19 0.60 ± 0.10 4.40 ± 2.14 0.65 ± 0.04 
P188 D1  
Control 3.92 ± 1.58 0.68 ± 0.10 3.11 ± 0.31 0.74 ± 0.09 
Treated 2.04 ± 1.08 0.63 ± 0.12 2.04 ± 0.97 0.63 ± 0.12 
P188 D7 
Control 3.46 ± 2.19 0.64 ± 0.09 4.99 ± 1.33 0.66 ± 0.07 
Treated 5.82 ± 5.59 0.46 ± 0.10* 4.07 ± 3.84 0.68 ± 0.09 
 
In the tibias, there was only a documented decrease in cortical bone thickness in 
the lateral plateau of the Recon group at 3-months. There were no documented changes in 






Table 7. Measured cortical bone parameters for each compartment of the tibia. 
Values reported as average ± standard deviation. * denotes significant difference 
between treated (right) limb to respective control (left) limbs. 
 
      Lateral Medial 
      Co.Po (%) Co.Th (mm) Co.Po (%) Co.Th (mm) 
1 mo. 
Recon  
Control 8.63 ± 4.5 0.64 ± 0.08 6.66 ± 1.89 0.74 ± 0.09 
Treated 7.28 ± 3.62 0.65 ± 0.07 6.32 ± 2.91 0.70 ± 0.04 
P188 D0 
Control 5.69 ± 3.14 0.66 ± 0.12 5.51 ± 3.22 0.79 ± 0.18 
Treated 3.96 ± 1.15 0.68 ± 0.08 4.21 ± 2.24 0.75 ± 0.09 
P188 D1  
Control 1.52 ± 1.39 0.67 ± 0.08 2.20 ± 1.30 0.71 ± 0.08 
Treated 3.37 ± 2.09 0.69 ± 0.11 3.71 ± 1.91 0.75 ± 0.09 
P188 D7 
Control 3.33 ± 1.88 0.63 ± 0.14 5.72 ± 3.11 0.75 ± 0.13 
Treated 2.19 ± 0.96 0.63 ± 0.05 3.73 ± 1.32 0.68 ± 0.07 
3 mo. 
Recon  
Control 7.90 ± 2.64 0.58 ± 0.12 8.28 ± 3.04 0.65 ± 0.09 
Treated 8.38 ± 3.69 0.46 ± 0.03* 8.32 ± 3.06 0.67 ± 0.13 
P188 D0 
Control 11.52 ± 1.91 0.62 ± 0.06 10.2 ± 5.56 0.70 ± 0.1 
Treated 5.62 ± 4.98 0.60 ± 0.15 3.51 ± 2.56 0.75 ± 0.09 
P188 D1  
Control 6.81 ± 2.16 0.69 ± 0.08 3.33 ± 1.99 0.77 ± 0.06 
Treated 3.12 ± 1.68 0.63 ± 0.07 3.51 ± 1.17 0.78 ± 0.1 
P188 D7 
Control 4.60 ± 0.98 0.70 ± 0.09 6.65 ± 0.87 0.72 ± 0.07 
Treated 3.27 ± 1.72 0.57 ± 0.08 2.63 ± 0.85 0.65 ± 0.06 
6 mo.  
Recon  
Control 8.60 ± 3.30 0.54 ± 0.04 9.36 ± 4.26 0.72 ± 0.13 
Treated 6.76 ± 1.57 0.57 ± 0.09 5.59 ± 0.84 0.7 ± 0.11 
P188 D0 
Control 5.80 ± 3.19 0.70 ± 0.09 7.31 ± 6.62 0.81 ± 0.13 
Treated 4.07 ± 2.24 0.70 ± 0.13 3.96 ± 1.58 0.77 ± 0.09 
P188 D1  
Control 3.61 ± 3.20 0.67 ± 0.02 4.37 ± 2.68 0.71 ± 0.04 
Treated 3.26 ± 2.01 0.60 ± 0.04 3.67 ± 1.78 0.76 ± 0.03 
P188 D7 
Control 6.58 ± 0.97 0.64 ± 0.08 5.74 ± 0.64 0.71 ± 0.09 
Treated 4.74 ± 3.21 0.68 ± 0.08 3.33 ± 1.07 0.77 ± 0.11 
 
Osteophyte Volume 
No osteophytes were documented in either the femurs or tibias of the control 
limbs. However, osteophytes were present in all treated limbs, regardless of treatment 
group. There was a significant increase in osteophyte volume in both the femur and tibia 
at all-time points, with more significant volume being found on the tibias. (Figure 24) In 
the tibias, larger volumes of osteophytes were found in the multiple dose treatment 
groups (P188 D1 and P188 D7 group) at 3-months, when compared to the Recon only 
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group. In the femur, the only documented difference in osteophyte volume was found 
between the P188 D0 6-month group compared to the Recon group at the same time 
point. (Figure 24) 
 
Figure 24. Osteophyte volume for femurs and tibias. Values reported as average ± 
standard error.  # denotes significant difference with the Recon group.  
 
Larger osteophyte volumes were more commonly observed in the compartment in 
which the bone tunnel was drilled during ACL reconstruction surgery; medial on the tibia 
and lateral on the femur (Figure 25).  
 
Figure 25. Representative images of a (A) tibia and (B) femur with osteophyte 
formation outside the normal joint margin. Areas enclosed with dotted lines 
represent osteophytic bone. Areas enclosed in the solid white circle indicate location 





  This animal model was successful in simulating acute knee joint damage by 
causing rupture or damage to the ACL and menisci. The model showed consistent signs 
of PTOA including osteophyte formation.  To the author’s knowledge, this is the first 
study to document changes in subchondral bone in a combined P188 and surgical 
intervention in-vivo animal model following traumatic injury to the knee to study the 
onset and progression of PTOA. This new model documented changes in the subchondral 
bone as early as 1-month following the traumatic impact. 
 Focusing on the Recon group in the current study, more significant changes in 
subchondral bone quality and morphometry were documented in the tibias compared to 
the femurs. These changes were more commonly documented in the medial compartment 
at 6-months post impact. Using the same closed-joint impact animal model as in this 
study, without surgical intervention, a previous study showed significant changes in both 
compartments of subchondral bone for impacted limbs at 3-months (12 weeks).128 Pauly 
et al. reported decreases in bone volume and mineral density as well as large osteophyte 
volumes, with larger volumes being documented in the tibias compared to the femurs. 
The Recon group of the current study showed similar trends in osteophyte volumes, 
however, the average value of 88 mm3 documented for tibias in the impact-reconstructed 
limbs was lower than the reported average 120 mm3 in the impact-only limbs. Osteophyte 
formation is thought to be caused by alterations in joint mechanics16,67,123, with Hsia et al. 
documenting an increase in osteophyte volume associated with a decrease in joint 
laxity.67 The data observed in the current study suggests that surgical intervention may 
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have been successful in returning some degree of normal knee kinematics, which in turn 
caused less formation of osteophytes and changes in subchondral bone health.  
In the current study, besides osteophyte formation, few consistent changes in bone 
quality or morphometry in any of the treatment groups were noted. The changes that did 
occur in trabecular bone were usually offsetting resulting in no overall effect in the bone 
volume to tissue volume ratio. For example, even though there was a decrease in 
trabecular number in the 1-month P188 D1 group, there was a slight increase in 
trabecular thickness and decrease in trabecular separation. Therefore, no overall change 
in bone volume was found. Similar trends were observed in the other morphometry 
values of trabecular bone. The lack of consistent significant changes could be attributed 
to the bone tunnels that were drilled into both the femurs and tibias during reconstruction 
surgery of the ACL.  
Previous studies assessing the effect of bone tunnels on bone health following 
ACL reconstruction surgery and the use of interference screws have shown that bone was 
able to remodel and return to normal architecture within months following 
surgery.70,83,136,150 In a canine model, Rodeo et al. showed progressive increases in bone 
ingrowth and mineralization 12- and 26-weeks post-surgery.136 In the current study, bone 
tunnels were present in the reconstructed limbs of all animals at 1-month, but the 
reconstructed limbs of animals in the 3- and 6-month time points were shown to have a 
small or no bone tunnels left. The tunnels were filled with new trabecular and cortical 
bone. Bone tunnels promoting bone growth and remodeling is further supported by the 
larger volumes of osteophytes being documented in the compartment in which the bone 
tunnels were drilled; that being the medial compartment on the tibia and the lateral 
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compartment on the femurs, as shown on Figure 25. This may suggest that the bone 
tunnels encouraged rapid bone remodeling in the reconstructed limbs, which aided in 
preventing significant changes in subchondral bone quality and morphometry, albeit at 
the expense of increased osteophytes.  
As PTOA is considered to be a disease of the whole joint, it is important to note 
and highlight the differences observed in other tissues that may have affected the 
response of subchondral bone. Previous studies have found that areas of meniscal damage 
are usually correlated directly with areas of articular damage73,152, which ultimately could 
affect the health of the underlying bone. As previously discussed in Chapter 3, when 
compared to their respective controls, more changes associated with PTOA were 
documented in the meniscus of the Recon group than in the P188 treated groups, 
especially at the later 6-month time point. Perhaps at the time points included in this 
study, the meniscus is performing its role within the joint and protecting the underlying 
articular cartilage, therefore few significant changes in subchondral bone health 
associated with the disease were observed. Ferretti et al., reported that patients who had 
tears in their meniscus and received a meniscectomy during reconstruction were more 
likely to develop the disease years following surgery, when compared to patients who 
received ACL reconstruction alone.45 These previous findings, paired with the current 
study, strongly suggest that meniscal health following traumatic injury to the knee joint 
may play a much more significant role in overall knee joint health and the onset and 
progression of PTOA.  
Some limitations of the current study include variations in locations of initial 
trauma. These locations may have been different in each animal, which could cause a 
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different response in bone resorption and remodeling of the subchondral bone. In order to 
determine the relationship between meniscal, articular cartilage, and subchondral bone 
health, future studies may want to include later time points to better assess the efficacy of 
surgical treatment, as well as combined P188 and surgical treatment, in limiting the 
disease.   
CONCLUSIONS 
 This is the first study to assess changes in subchondral bone following combined 
P188 and surgical treatment. As osteophyte formation was the only changes associated 
with PTOA documented in all of the treatment groups, the current study suggests that 
reconstruction surgery alone may be able to limit changes in the tissue.  Including a later 
time point may find the effectiveness of P188 treatment in preventing PTOA changes in 






DETERMINING THE PRESENCE OF BIOMARKERS ASSOCIATED WITH 
PTOA IN THE SYNOVIAL FLUID  
 
INTRODUCTION 
 It has been established that surgical intervention following damage to the anterior 
cruciate ligament (ACL) and meniscus caused by a traumatic impact to the knee joint 
does not decrease the likelihood of a patient developing post-traumatic osteoarthritis 
(PTOA) years after the surgery.46,50,115,131 Synovitis, inflammation of the synovium, is 
one of the early signs of PTOA and has been suggested to be a leading cause of pain in 
patients suffering from PTOA.75,141,142 Synovitis is marked by hypervascularization of the 
synovium membrane, thickening of the lining cells, an increase in synovial fluid (SF) 
volume and secretion of biomarkers that cause further inflammation and degradation of 
the tissues within the joint.15,75,142 As surgical intervention only addresses macroscopic 
damage to the tissues, it is believed that pharmaceutical treatment may be able to address 
the occult damage and aid in limiting changes in biomarker expression within the joint.  
 Poloxamer 188 (P188) has been shown to inhibit cell death in articular cartilage 
and meniscal explants following traumatic impact.8,9,53,117,118,130 A single 8mg/mL dose of 
P188 has been shown to inhibit pathways associated with cell death, inflammation, and 
matrix degradation.9 These findings suggest that P188 treatment may be able to help limit 
changes in the expression of biomarkers associated with PTOA and merits further in-vivo 
investigation. Thus, proteome analyses which can help determine a wide range of protein 
expression potentially affected by P188 treatment has not been performed. Additionally, 
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proteome analysis could help determine other key biomarkers and pathways the 
surfactant may be affecting.  
 Proteomic analysis of the SF from both human and animals has become a popular 
tool used to identify biomarkers linked with the pathology of PTOA.10,66,72,92,95,96,135,156,158 
Currently, the only studies evaluating changes in the proteome of lapine SF have either 
used an ACL transection model or injected monosodium iodacetate to induce 
PTOA.92,95,96,156,158 Although these previous studies were successful in identifying 
biomarkers associated with PTOA, the clinical relevance of these findings are limited 
since these models were either surgically or chemically induced rather than resulting 
from a traumatic closed-joint injury. To the author’s knowledge, changes in the SF 
proteome of a closed-joint impact and reconstruction model have not been reported.  
 The goals of the study were to assess the proteome of the SF in a closed-joint 
impact and surgical intervention model and to test the efficacy of combined surgical and 
intra-articular P188 treatment in preventing the expression of biomarkers associated with 
PTOA.  It was hypothesized that biomarkers associated with the disease would be 
differentially expressed in the reconstruction only group and that combined P188 and 
surgical treatment would be more effective in mitigating changes in the expression of 
biomarkers associated with the disease in the SF.   
 
METHODS 
Animal Model  
For more information regarding the Animal Model, treatments, and total number 
of samples used in the study, refer to the Methods section of Chapter 3.  
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Synovial Fluid Harvesting 
Following euthanasia, the SF was immediately harvested from both knee joints by 
injecting 1.5cc of sterile 1x PBS using a 3cc syringe into the knee joint (Figure 26). 
While the syringe was in the knee capsule, the joint was articulated/flexed 10 times to 
ensure homogeneous fluid distribution. Fluid within the joint was then aspirated using a 
syringe, transferred to a sealed tube, and stores at -80C for further analysis.  
 
Figure 26 Synovial fluid being extracted from a rabbit knee joint using a syringe. 
  
While samples from the P188 D0 treatment group and 3-month time point for all 
treatment groups were available, they were not included in the SF study due to 
unsatisfactory sample quality for proteomic analysis (i.e. varying volumes between 
treated and control limbs from each animal, blood contamination, etc.).  Information 
regarding the treatment groups, time points, and animal sample size for each can be found 
in Table 8.  
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Table 8 Sample sizes included in the analysis of SF proteome for each treatment 
group and time point. 
Group 1 mo. 6 mo. 
Reconstruction (Recon) 3 3 
Reconstruction + P188 Day 0 & 1 (P188 D1) 3 3 
Reconstruction + P188 Day 0, 1, & 7 (P188 D7) 3 2 
 
Sample Preparation 
Samples went through a CaptureSelect MutliSpecies Albumin depletion column 
(#191085310, Thermo Scientific) per manufacturers specification to remove albumin, 
which is one of the most abundant proteins found in SF. Briefly, samples were thawed on 
ice and 200 uL of the depletion product were loaded onto a spin column and hydrated 
with 1x PBS three times and centrifuged at 3000 rpm for one minute. Once thawed, 
200uL of SF sample were loaded into each spin column and were allowed to incubate at 
room temperature for 20 minutes, while occasionally vortexing. Flow through was 
collected by centrifuging the spin columns with sample at 3000 rpm for one minute and 
washed with 100 uL of 1x PBS twice.  
Protein concentration for each sample were quantified via a bicinchoninic acid 
(BCA) protein assay with a standard curve reference of bovine serum albumin (BSA) 
from 0.125 – 2 mg/mL, and digested with 1 μg/mL hyaluronidase for 3 hours at 37°C 
with shaking at 750 rpm.  Digested samples were then reduced with 5 mM DTT for 1.5 
hours at room temperature and alkylated in darkness with 10 mM iodoacetamide for 45 
minutes at room temperature. 100 μg of each sample was aliquoted for trypsin digestion 
overnight at a 1:20 protease:substrate ratio and subsequently desalted over Pierce C18 
columns (#87851) per manufacturer’s instructions.  100 ng of each sample was screened 
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by liquid chromatography-mass spectrometry (LC-MS) to verify digestion efficiency and 
peptide content.   
Tandem Mass Target (TMT) Labeling 
Desalted and screened samples were fully dried and resuspended in 50 mM 
triethylammonium bicarbonate (TEAB) and quantified by A280 measurements assuming 1 
A.U. = 1 mg/mL.  Per manufacturer’s instructions, TMT reagents were equilibrated to 
room temperature and resuspended in 41 μL of anhydrous acetonitrile.  Eighty μg of each 
sample were diluted to 100 μL total volume and reacted with a TMT reagent for 1 hour at 
RT.  The reaction was quenched with 8 μL of 5% hydroxylamine for 15 minutes, dried 
completely, acidified, and desalted over Pierce C18 columns (#87851) with 5 total wash 
steps for complete removal of unreacted reagent.  100 ng of each sample were screened 
for labeling efficiency by LC/MS. 
Sample Pooling and LC-MS Analysis 
After verifying > 98% labeling efficiency for all samples, 3 μg of each sample 
was pooled within each plex of 6 and all plexes were diluted to equal total peptide 
concentrations.  Samples were subjected to mass analysis using a Thermo Scientific 
Ultimate 3000 RSLCnano ultra-high-performance liquid chromatography (UPLC) system 
coupled to a high-resolution Thermo Scientific Q Exactive HF mass spectrometer.  An 
aliquot of each peptide preparation in Solvent A (0.1% formic acid in H2O) was injected 
onto a Waters BEH C18 analytical column (2 µm, 100 Å, 75 µm x 25 cm) and separated 
by reverse-phase chromatography over a 180-min gradient at 300 nL/min flow.  Peptides 
were eluted directly into the QE-HF using positive mode electrospray ionization.  MS 
scan acquisition parameters were set to 120,000 resolution, 1e6 AGC target, maximum 
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ion time (MIT) of 50 ms, and a mass range of 375-1400 m/z.  Data dependent MS/MS 
scan acquisition parameters were set to 30,000 resolution, 1e5 AGC target, MIT 100 ms, 
loop count of 15, isolation window of 0.7 m/z, dynamic exclusion window of 30 s, a 
normalized collision energy of 33, fixed first mass of 100 m/z, with peptide match set to 
preferred and charge exclusion enabled for all unassigned, +1, and >+8 charged species. 
Sample screens for peptide content and labeling efficiency were analyzed with a 60-min 
UPLC gradient using the following MS acquisition parameters: MS scan resolution 
60,000, MIT of 60 ms, mass range 300-1800 m/z; MS/MS scan resolution 15,000, MIT 
40 ms, isolation window 2.0 m/z, normalized collision energy of 27.   
Protein Identification and Quantification  
Raw data files were uploaded into Proteome Discoverer v2.5 (Thermo Scientific) 
and searched using Sequest HT search engine against the Uniprot Oryctolagus cuniculus 
UP000001811 reference proteome database (accessed 20210608 and last updated 
20210129) using the following parameters: trypsin enzyme specificity with 2 maximum 
missed cleavages, minimum and maximum peptide lengths of 6 and 144, respectively, 
static modifications of TMT6plex on peptide N-termini and Lys side chains, 
carbamidomethylation on Cys, and dynamic modifications of oxidation on Met, 
deamidation on Asn and Gln, protein N-terminal acetylation. Precursor and fragment 
mass tolerances were set to 10 ppm and 0.02 Da, respectively. All data were filtered to a 
strict 1% false discovery rate at the peptide spectrum matches, peptide, and protein levels. 
For TMT six plex-based reporter ion quantitation, the following parameters were used: 
quantitative value corrections set to “true,” a co-isolation threshold of 50, minimum 
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channel occupancy threshold of 32%, total peptide amount normalization “on,” and 
protein ratio calculation was set to “Protein Abundance Based.” 
Statistics  
 To ensure high quality samples for TMT analyses, 1-month and 6-month samples 
were combined for each treatment group. Paired student t-tests were used to determine 
significant difference for protein expression levels between treated samples and 
respective controls. Samples with an Abundance Ratio Variability ≤ 20 and a p-value < 
0.05 were deemed significant. For all statistical results, the ratio of protein expression in 
the treated (right) limbs over the protein expression in the control (left) limbs for each 
treatment group will be used.  
RESULTS 
 In total, 714 proteins were identified between all of the samples included in the 
study. Comparing the control limbs of all treatment groups to each other found a total of 
707 proteins, with 688 proteins being shared between the three different conditions 
(Figure 27A). Comparing the treated limbs of all treatment groups to each other found a 
total of 708 proteins, with 704 proteins being shared between the three different 
conditions (Figure 27B). Further analysis of the proteins that were exclusively expressed 
in one of the treatments or limbs found that these proteins were not associated with 
PTOA, inflammation or any other pathways of interest. Comparing the expressed ratios 
of treated limbs to control limbs for each condition found a total of 19 significant proteins 
(Figure 27C). Comparing the overlap between the ratios of the significantly expressed 
proteins in the three treatment groups found proteins that were present in more than one 
treatment group. More information regarding the significantly expressed proteins for each 
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treatment group, along with definition name, p-value, and ratio can be found in Tables x-
x.  
 
Figure 27. Total number of proteins and overlap for (A) control limbs of each 
treatment group, (B) the treated limbs of each treatment group, and (C) the total 
significant (ARV ≤ 20, p-value < 0.05) expressed proteins based on abundance ratio 
for each treatment group.  
 
In the Recon group, out of 708 total proteins found in both treated and control 
limbs, there were seven significantly differentially expressed proteins (Figure 27C). Two 
proteins were expressed at lower levels (intercellular adhesion molecule 5, proteoglycan 
4, and mimecan) and four proteins (periostin, coagulation factor V, tenascin C, and 
cystatin F) were expressed in higher levels in the treated limbs compared to controls 
(Table 9). A ratio < 1 means that the protein was under expressed in the treated limbs 
compared to control limbs and a ratio > 1 means that the protein was over expressed in 
the treated limbs compared to control limbs.  
Table 9. Protein content ratios of the reconstruction limb and respective control 
limb (Recon group) for significantly differentially expressed proteins. 
Protein ID Definition name P-value Ratio 
Q28730 Intercellular adhesion molecule 5 0.007144 0.322 
G1TFQ7 Proteoglycan 4 0.000823 0.371 
Q8MJF1 Mimecan 0.005963 0.453 
A0A5F9CD23 Periostin 1.18E-06 2.121 
A0A5F9CYY5 Coagulation factor V 0.000519 2.441 
A0A5F9DIW0 Tenascin C 0.003623 2.493 
A0A5F9DM57 Cystatin F 0.003817 2.73 
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In the P188 D1 group, out of a total of 707 proteins found in both treated and 
control limbs, there were two significantly differentially expressed proteins (Figure 27C). 
Mimecan was expressed at lower levels and proteasome subunit alpha type was expressed 
at higher levels in the treated limbs compared to controls (Table 10).  
Table 10. Protein content ratios of the reconstruction and P188 Day 0 & 1 limb and 
respective control limb (P188 D1 group) for significantly differentially expressed 
proteins 
Protein ID Definition name P-value Ratio 
Q8MJF1 Mimecan  0.00577 0.371 
G1T2L1 Proteasome subunit alpha type 0.001559 2.408 
 
 In the P188 D7 group, out of a total of 708 proteins found in both treated and 
control limbs, there were ten significantly differentially expressed proteins (Figure 27C). 
Only one protein was expressed at lower levels and nine proteins were expressed at 
higher levels in the treated limbs compared to controls (Table 11). One of the higher 
expressed proteins was an uncharacterized protein for which further information 
regarding its definition name and function could not be found. 
Table 11. Protein content ratios of the reconstruction and P188 Day 0, 1, & 7 limb 
and respective control limb (P188 D7 group) for significantly differentially 
expressed proteins. 
Protein ID Definition name P-value Ratio 
G1SXM9 
Lymphatic vessel endothelial hyaluronan 
receptor 1 
0.002463 0.415 
A0A5F9C5Y4 Phosphoacetylglucosamine mutase 0.005568 2.002 
A0A5S8HX12 Translationally-controlled tumor protein 0.022714 2.107 
A0A5F9C869 G2/M-phase specific E3 ubiquitin protein ligase 0.007858 2.228 
P07452 Carbonic anhydrase 1 (Fragment) 0.008052 2.316 
A0A5F9D6A8 Uncharacterized protein 0.007858 2.547 
G1T2L1 Proteasome subunit alpha type 0.008028 2.687 
G1T5H0 HtrA serine peptidase 1 0.029372 2.728 
A0A5F9DIW0 Tenascin C  1.97E-05 2.746 





 The present study is the first to perform proteomic analysis of SF in a combined 
P188 and surgical intervention in-vivo lapine model following traumatic injury to the 
knee to study the onset and progression of PTOA. The results of the study found that 
although the proteomes of the SF from the three treatment groups were mostly similar, 
there were a few significantly expressed proteins between the three treatment groups that 
are associated with PTOA.  
 More proteins whose change that are strongly associated with PTOA were found 
in the Recon only group, compared to the P188 treatment groups. In the current study, it 
was found that proteoglycan 4 (PRG4) was expressed at lower levels and that periostin 
(Postn) and tensacin C (TNC) were expressed at higher levels in the treated limbs 
compare to control limbs. PRG4 provides lubrication within the knee joint and is 
commonly found in the SF and the surfaces of articular cartilage and menisci.76,77,133 
Animal studies have reported that lower levels of the protein are associated with cartilage 
degeneration and as an early sign of PTOA.37,169 An increase in Postn expression has 
been found to be induced following knee joint trauma and has been shown to be 
increased in mouse and human cartilage samples during the progression of osteoarthritis 
(OA).7,26 In an ACL transection knockout mouse model, Attur et al reported that a 
deficiency in Postn provided a protective effect against PTOA6, further highlighting the 
relationship between the protein and PTOA. Similarly, higher levels of TNC have been 
documented in multiple studies investigating the relationship between the protein and 
PTOA suggesting that the protein is a useful marker of disease progression.60,61,116,125 In a 
canine model, Chockalingam et al. found an immediate increase in the expression of 
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TNC, which decreased over time, but was still expressed at higher levels compared to 
controls 12-months following joint trauma.27 The changes in expression levels of these 
proteins suggest that reconstruction surgery alone is not able to fully mitigate the disease.  
 P188 treatment seemed to have helped prevent the expression of most of the 
proteins previously discussed. In the P188 D7 group, had a few proteins that have been 
shown to be associated with PTOA. TNC was the only significantly expressed protein at 
higher levels in the P188 D7 groups, similar to the Recon only group, but the other 
proteins, PRG4 and Postn, were not differentially regulated in either P188 treatment 
groups. In the P188 D7 group, both HtrA and carbonic hydrase 1 were found to be 
expressed at higher levels in the treated limbs compared to control limbs. Hu et al. 
reported a 7-fold increase in levels of HtrA, whose genetic code is conserved among 
mammals, in cartilage explants from OA patients, compared to non-OA controls.68 
Higher expression of carbonic hydrase 1, which promotes the formation of calcium 
carbonate in bone, were found in synovial tissues of patients suffering of end stage OA, 
compared to patients suffering of rheumatoid arthritis (RA).23 Although there is a 
distinction between PTOA/OA and RA, it is interesting to note that a protein that has 
been shown to be overly expressed in the latter was found in the P188 D7 group, the 
translationally controlled tumor protein (TCTP). Kim et al. reported that TCTP triggers a 
histamine response and levels of the protein are correlated with RA disease progression 
along with inflammation.81 While P188 treatment may not have been able to fully prevent 
the onset of PTOA, the results suggest that P188 may limit the number of biomarkers 
associated with the disease.  
 
90 
Previous studies have reported an increase in mimecan (MIME), a small 
proteoglycan which supports the collagen matrix, expression in hip cartilage from OA 
patients.66 However, the current study found MIME to be expressed at lower levels in 
both the Recon and P188 D1 groups. The differences between the current and previous 
findings could be attributed to the time point in which the samples were obtained, as 
Hosseininia et al. used end-stage cartilage samples from patients vs. the current study that 
was within 6 months of an injury inducing impact.66 Proteasome subunit alpha type was 
found to be significantly expressed in both the P188 D1 and P188 D7 groups. 
Unfortunately, due to the lack of clarification regarding the exact type of proteasome 
subunit alpha type, the current study was limited in investigating the role of this protein 
within the knee joint and disease pathology. Other proteins found, but that were not 
discussed due to a lack of previous detailed research describing the function of the 
proteins include: intercellular adhesion molecule 5, coagulation factor v, cystatin F, 
lymphatic vessel endothelial hyaluronan receptor 1, phosphoacetylglucosamine mutase, 
G2/M-phase specific E3 ubiquitin protein ligase, and collagen type V alpha 2 chain. 
Limitations of the current study include limited sample sizes for each treatment 
group and time point. Similarly, varying sample sizes within each treatment group may 
have affected the results, especially for the P188 D7 group. Future studies should aim to 
account for possible unsatisfactory sample quality for proteomic analysis by increasing 
the sample size in each group. Another limitation is the exclusion of an impact only 
group, which would help divorce the effect of surgical intervention on the expression of 
biomarkers on the disease compared to those that may be present following a traumatic 
impact alone. As previously mentioned, this study combined samples across time points 
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to increase the sample size for each treatment and ensure high quality samples for TMT 
analyses. Previous studies have shown that both progression of the disease and protein 
expression are time dependent. Currently, there is another proteomic analysis being 
conducted with the samples used in this study that will include a variable for time point. 
This will help determine changes in the proteome across time, which could identify other 
proteins that play a key role in the onset and progression of PTOA.  
CONCLUSIONS 
 This was the first study to analyze the proteome of SF in a closed joint impact and 
reconstruction model and a combined P188 and surgical treatment model. Biomarkers 
associated with PTOA were found to be elevated in the Recon group and not in the P188 
treated groups, perhaps suggesting that reconstruction surgery alone may not be able to 
prevent the development of PTOA. Combined P188 and surgical treatment proved to be 
able to significantly limit the expression of these biomarkers, which could prove to be 
















CONCLUSIONS AND FUTURE WORK 
 The work presented in the preceding chapters provided an investigation into the 
use of combined single and multiple administrations of P188 and surgical reconstruction 
in an in-vivo closed-joint impact lapine model as potential treatment to help limit, delay, 
or mitigate the onset and progression of PTOA by assessing changes in multiple tissues 
within the knee joint. As it had been hypothesized that surgical intervention fails to 
address the occult damage to the tissues within the knee joint following mechanical 
trauma, P188 was chosen as previous studies had shown that the surfactant significantly 
prevented cell death following an injurious impact in in-vitro and in-vivo studies. 
Similarly, the surfactant has been shown to inhibit pathways associated with cell death, 
inflammation, and matrix degradation.  
The results of the current study found that reconstruction surgery alone does not 
prevent the onset and progression of PTOA. Changes associated with the disease were 
found in all three of the analyzed tissues as early as 1-month following impact, with the 
severity of these changes increasing over time. Most of these changes were found in the 
meniscus, with an increase in tissue damage, decreases in the mechanical properties and 
loss of proteoglycans being reported. Proteomic analyses found that more proteins 
associated with the disease were expressed in the synovial fluid of the reconstructed only 
limbs as well, which could cause further degradation to other tissues within the joint. The 
only significant change found in the subchondral bone was the formation of osteophytes, 
which are one of the key markers used to diagnose the disease using non-invasive 
imaging modalities. The changes reported in the current study are corroborated by 
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findings in the clinical setting following surgical intervention and further highlight the 
need to find alternative or adjacent treatments to limit or prevent the disease.  
Tying together the documented changes in the current study, it can be 
hypothesized that perhaps the decrease in the expression of Proteoglycan 4, which aids in 
lubrication within the joint, could be contributing to the early degeneration observed in 
the meniscus at the 1-month time point. A decrease in lubrication could be subjecting the 
tissue to more friction, which could be contributing to the increase in damage observed 
across all time points in the Recon group, as a decrease in Proteoglycan 4 was only 
observed in this treatment group, and not in any of the P188 treated groups analyzed. 
Similarly, higher expression of periostin and tenascin C have been observed in patients 
with more severe OA. These increases in the expression of both proteins in the Recon 
group could be contributing to the degradation documented in the mechanical properties 
and proteoglycan content of the meniscus, as these properties were much more negatively 
affected. These finding suggest that the menisci were effective in performing their role in 
protecting the underlying articular cartilage and subchondral bone, as few changes were 
documented in subchondral bone health.  
A single or multiple administrations of P188 treatment, in conjunction with 
surgical intervention, proved to be able to limit the progression of PTOA, when 
compared to reconstruction surgery alone. In the meniscus, P188 treatment was able to 
prevent gross morphological changes in the lateral meniscus at the 1-month time point, 
but damage progressed in the tissue over time. All P188 treatment groups had less 
significant changes in both the mechanical properties and loss of proteoglycan content at 
later time points. Analyzing the proteome of the synovial fluid of the P188 D1 and P188 
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D7 groups found less significantly expressed proteins associated with PTOA, when 
compared to the reconstructed only group. Perhaps by inhibiting cell death post-impact, 
P188 treatment may have reduced the expression of the biomarkers associated with 
PTOA found in the Recon group, which could explain the less significant changes 
observed in these treatment groups. In the subchondral bone, there were few documented 
changes in architecture, or mineral composition, when compared to reconstruction only. 
The collaborating laboratory found that P188 treatment was able to prevent significant 
changes in the articular cartilage, suggesting that by maintaining the health of the tissue, 
the underlying bone was protected. The only consistent change found in subchondral 
bone linked with the onset and progression of the disease was the formation of 
osteophytes outside the normal joint margin, which could be associated with the higher 
expression of carbonic hydrase 1 found in the synovial fluid. At the 6-month time point, 
although not statistically significant, larger volumes of osteophytes were documented in 
the P188 D7 bones compared to the Recon group.  
However, this study was not without large scale limitations. One limitation was 
the use of the animals left limb as the contralateral control instead of limbs from animals 
that received no treatment to any of their limbs. As it was noted, following both the 
traumatic impact and surgical intervention, the animals favored the untreated limb for a 
few days. These changes in gait could have resulted in long term changes in loading on 
the left limb of the animals. Additionally, cytokines from the treated limbs could have 
been secreted from the synovium into the blood stream, which could have affected the 
cytokines found in the control limb. Another limitation was the rate at which the impact 
was delivered, as knee injuries as a result from recreational activities or car crashes are 
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around 200 ms and the current study delivered the impact at 500 ms. The difference 
between the two rates could affect the amount of damage observed within the knee joint 
and perhaps the rate at which the diseases progressed over time. In the current study, the 
compressive modulus and GAG content of meniscal tissue were studied instead of 
collagen and tensile properties because it was expected that the traumatic impact and 
meniscectomy would cause the tissue to be heavily damaged. This would compromise the 
dog bone shapes that could be obtained from each sample. Currently, one of the most 
popular and reliable ways to determine collagen content within soft tissues is via 
immunohistochemistry. This methodology would be challenging in the current study due 
to the samples originating from rabbits, which would make it difficult to find antibodies 
that would be compatible with the samples. Despite these limitations, the findings of the 
study provided great insight into disease progression and alternative treatment options.  
The findings of the current study suggest that, when compared to reconstructive 
surgery alone, combined P188 treatment and surgical intervention were able to limit the 
progression of the disease. Inflammation caused by surgical intervention may be 
attributed to some of the observed changes associated with PTOA in this model. Perhaps 
another administration of P188 immediately following the surgery may help reduce 
inflammation and limit the disease. Future studies may want to consider a targeted 
treatment of P188, as in the current study, it was unclear if the positive effects observed 
in the P188 treated limbs were due to direct or indirect treatment. Finding methods to 
track the surfactant as it is being diffused throughout the knee joint, such as radio or 
fluorescent labeling, would help determine which tissues P188 is directly helping and 
which ones are being indirectly affected by the treatment. Alternative meniscal 
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replacement options should be considered, as it has been well documented that 
meniscectomies lead to changes in joint loading and have a greater impact on whether or 
not a patient will require total knee replacement later in life. Combined treatments such 
as; surgical intervention to address the macroscopic damage and reduce joint laxity, P188 
administration after injury and surgery to prevent cell death following each stressful 
event, and a total meniscal replacement to aid in load distribution and protect the 
underlying cartilage, may prove to be better treatment options to prevent the onset and 
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Appendix A Meniscus Live/Dead Protocol 
Equipment/Supplies: 
Item Location 
Specimens (Meniscus) Incubator 
Scalpel Dissection Tools Drawer 
Tweezers 
0.9% Saline Solution 
Drop cloth  
15 mLTest Tubes  Top of Incubator 
Micron tube strips (2-4 depending on 
sample size) 
On shelf above Cell Culture Supply drawer 
Micron test tube holder Next to micron test tube strips 
Micro pipets (grey, orange, yellow) On counter  
0.6mL MicroCentrifuge Tube Cell Culture Supplies Cabinet 
4 Pipet tips  On counter 
Calcein In freezer in small cylindrical container (Freezer 
room) Ethidium Homodimer-1 
Un-subbed slides  Glass Slides shelf  
DI water On counter 
Sharps Container Under dissection table 
Portable Hard Drive In portable hard drive drawer 
 
Steps for preparation 
1. Place 3 rows of micron tubes in the micron test tube holder 
a. One row for PBS to keep samples hydrated 
b. One row for Calcine/Ethidium mix   
c. One row for PBS washing step  
2. Fill two rows (or one depending on number of samples) with PBS 
3. Fill 15mL test tube with 4 mL of PBS 
4. Fill 0.6mL microcentrifuge tube with 400uL of 10% formalin 
a. Use one tube per sample 
5. Remove Calcein and Ethidium from freezer so they can start to thaw 
a. Be sure to keep them un exposed to the lights 
6. Turn on Incubator (~ 37 degrees Celsius) 
7. Set all pipettes to appropriate measures 
a. Grey top – 3 uL 
b. Orange top – 8 uL 
c. Yellow top – 150 uL 
 
Steps for Slicing 
1. Pour PBS from test tube into waste beaker 
2. Take as thin of a slice (~0.5mm) from the cut face of the specimen 
3. Place thin slice in micron vile 
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4. Place rest of sample in formalin microcentrifuge tube 
5. Repeat for all specimens with enough testable tissue 
 
Steps for Staining  
1. Turn off lights 
2. Add 3uL of Calcein (grey pipette) to 15mL test tube 
1. Add 8uL of Ethidium  (orange pipette) to 15mL test tube 
2. Return Calcine and Ethidium vials to freezer 
3. Vortex both test tube to mix stain into PBS 
4. Pipette 150uL into empty micron test tube rows 
5. Transfer meniscal slices from PBS micron test tube rows to fluorescence rows 
6. Cap the rows 
7. Slightly shake rows to mix 
a. Be sure not to mix up what specimen is what 
b. Make sure all meniscal slices are at bottom of test tube 
8. Place in incubator for 25 mins 
9. Remove from incubator 
10. Move to meniscal slices to PBS micron test tube rows 
11. Place in incubator for 5 mins for a “wash” 
12. Remove from incubator  
13. Turn off incubator 
14. Remove slices from PBS and place on un-subbed slides 
15. Cover specimens with DI water to stay hydrated 
 
Steps for Imaging in Animal Cancer Center (ACC) 
Make sure that slides are properly covered to prevent photo bleaching when transporting 
to ACC 
1. Log hours 
2. Log onto computer using regular engineering log in 
3. Turn off light 
4. Turn burner on 
a. Wait for green light 
b. If green light doesn’t come on turn off let rest for 3 minutes and try again 
5. Turn scope on  
a. Make sure shutter is off 
6. Be sure in 2x 
7. On Desktop open Q capture 
8. Switch scope to camera 
9. Will use green filter to image red (~600-900ms VERY variable) 
10. Will use blue filter to image green (~1-2s but VERY variable) 
11. Take photos of each image and save 
a. Name each image after the meniscal sample  
 
Steps When Done Imaging 
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1. When all images have been taken close Q capture 
2. Close shutter 
3. Turn scope off 
4. Turn burner off 
5. Record hours 
6. Log off computer 





Appendix B Cryo-Embedding of Soft Tissue Protocol 
 
Equipment/Supplies 
Item Amount Location 
Phosphate Buffered Saline 
(PBS) 
NA PBS Storage Tank 
Chemistry Grade Crystalline 
Sucrose 
Various  
Tissue Tek OCT 1 Tube Shelf with embedding 
supplies 
Tissue Tek Cryomolds NA Shelf with embedding 
supplies 
Liquid Nitrogen 1 Dewar  
Styrofoam bowl 1 Tissue Tek Cabinet 
Forceps/Tweezers 1 pair Dissection Tools Drawer 
Plastic Wrap 1 box Shelf with embedding 
supplies 
Weigh Boat 1 Drawer Under Scale 
Beakers 3-4 Glassware Shelf 
 
Prepared Solutions: 
• 10% sucrose solution: 
1. Dissolve 10g crystalline sucrose in 100ml PBS. 
• 20% sucrose solution: 
1. Dissolve 20g crystalline sucrose in 100ml PBS. 
• 30% sucrose solution: 
1. Dissolve 30g crystalline sucrose in 100ml PBS. 
Methods 
1. Fill 100 mL glass beakers approximately half or ¾ full with 10% 20% and 30% sucrose 
solutions respectively. 
2. Place specimen into 10% beaker; the tissue should float. 
3. Once the tissue drops to the bottom of the vial tissue has been infiltrated, move tissue to 
20% beaker and repeat. 
4. Once the tissue drops to the bottom of the vial, transfer tissue to 30% sucrose solution  
5. Once the tissue drops to the bottom of the vial, remove tissue from vial and blot with 
Kimwipes. 
6. Put small amount of OCT into a weight boat –  
o This will be used to apply a small amount of OCT to the cutting face of each 
specimen to aid in position detainment in cryo-mold during the freeze cycle. 
7. Cut tissue if necessary to attain a flat cross section and orient appropriately in cryo-mold 
with the cut face lying flat on the bottom of the mold 
8. Cover fill mold with OCT. 
9. Pour liquid nitrogen into Styrofoam dish. 
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10. Carefully submerge tissue/mold in liquid nitrogen so as not to disrupt orientation of tissue 
in the mold. 
11. Once the sample sinks to the bottom of the dish, remove and place on absorbent towel 
(slows down thawing of frozen specimen/OCT).  
12. Allow sample to rest at room temperature for a minute to bring up to a temperature that is 
safe to handle and then remove from mold and wrap immediately cover with plastic 
wrap, label and store at -20°C. 
 
Notes: 
• Puck should “pop” out of sample. Be careful not to crack tissue/medium by forcing the 
puck to pop out. 





Appendix C Cryo-Sectioning of Soft Tissue Protocol 
 
Equipment/Supplies 
Item Amount Location 
Cryostat 1 Histology room 
Tissue Tek OCT 1 Tube On top of cryostat 
Subbed Slides NA Drawer next to cryostat 
Brush 1 Inside of cryostat 
EtOH in Spray Bottle 1 Sprayer Next to cryostat 
Methods 
 
1. Turn on the cryostat and let it reach -20˚C prior to using! This may take an hour or 
more depending on the outside temperature. Make sure to turn off the cryostat if it 
will not be in use for an extended period of time (more than 72hrs). 
2. Inside the microtome, place the gold chuck (grooved platform) in one of the first 
four holes in the “fast freeze rail” (2 columns of 6 holes each located on the far left 
inside the microtome).  These chucks can be left in the cryostat during cool-down 
time as well.  
o `The slots are NOT numbered – make sure to label the order of your samples 
if you are prepping more than one sample at a time.  
3. Remove a blade from the blade container, or reuse one designated for your tissue, 
and grip it by the flat edge.  Raise the clamp on the right hand side of the blade 
holder and slide the blade in along the left hand side of the blade holder.  If it won’t 
go in, push gently on the bottom edge of the blade holder (the side closest to you).  
Push the clamp back up to lock the blade in place. 
o Inspect the blade before putting it into the blade holder. Do not reuse the 
blade if there are any cosmetic defects, cracks, or chips taken from the blade. 
4. Wearing gloves remove the chuck and hold the post in your hand, letting it warm up 
slightly.  Spread embedding medium on the face of the chuck (over the grooved 
surface, making sure it goes down into the grooves), and put the chuck back in the 
fast freeze rail hole.  NOTE: if the chuck is too cold when you put the medium on the 
grooved face, the medium will not go down into the grooves. You will have to pop off 
the frozen medium, wait for the chuck to warm up a bit more, and try again.   
5. As soon as crystals start to appear on the outside edges of the embedding medium 
on the chuck face (this will happen quickly, and the medium will turn white near the 
chuck), push your embedded specimen into the center.  The cutting surface (flat 
surface) should be exposed and parallel with the chuck surface.  
6. Allow the entire chuck/specimen combination to freeze inside the cryostat. Keep 
window on cryostat closed during this period.  
7. Insert the post of the chuck into the chuck holder.  The small metal knob behind the 
chuck holder secures the chuck in the holder, and the black knob behind the 
blade/chuck allows the chuck to rotate once it has been loosened. 
8. Adjust the vertical position of the sample with the handwheel so that it is centered 
vertically with respect to the blade. 
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9. Use the retract button on main screen of the cryostat to move chuck and holder 
away from blade. Make sure the notch needle on the displacement wheel is up when 
this is done. 
10. Use the advance button on main screen of the cryostat to move chuck and holder 
toward the blade. Make sure the notch needle on the displacement wheel is when 
this is done. 
11. Using the handwheel on the right hand side of the cryostat, raise and lower the 
embedded sample to trim through the frozen medium until you start to see the 
sample appear. Continue trimming until a good cross-section appears.  Adjust the 
angle of the chuck if the sample appears to be cutting unevenly (i.e., if sections 
appear to be thicker on one side, if they appear angled, etc.). There is no blade 
guard, so MAKE SURE TO BE CAREFUL TO NOT CUT YOURSELF WITH THE BLADE 
when you do this.  
12. Flip the “glass anti-curl plate” up so that any sections cut will slide into it 
underneath the glass; this will prevent sections from curling. 
13. Start with 6um sections and increase to 8um if 6um does not yield good sections. 
Raise the glass plate periodically to clean out any “junk sections” with the brush 
kept inside the microtome 
14. When your first good (even thickness, longitudinal appearance) section is cut, 
transfer it to a piece of slide glass by raising the anti-curl plate and pressing a piece 
of slide glass against the specimen.  
15. Cut at least 2 more sections that you’ll dispose of before the next section you plan to 
transfer to a slide (so that they’ll be separated through the depth of the core).  Do 
not place more than 3-4 sections per slide or the cover glass will not fit.  Be careful 
of their placement when transferring to the slide glass – you won’t be able to move 
them once they’ve been stuck to the slide, so make sure they’re close enough 
together so that one coverglass will cover all 3.  Obtain a total of 9 sections (2-3 per 
slide; 3-4 slides) per sample.  
16. The remaining specimen can be refrozen by carefully melting the OCT medium from 
the underside the chuck with your fingers. DO NOT let the sample melt. Refold the 
sample in saran wrap and place in -20˚C non-frost free freezer. 
17. Remove the blade from the cryostat; raise the blade clamp to unlock it and use 
forceps to gently push along the right hand side of the blade, pushing the blade out 
the left side of the holder. Place the used blade in the disposal side of the blade 
container. 
18. Pull up the notch needle on the displacement wheel and push the “RETRACT” button 
to the left of the cryostat menu panel to retract the chuck and holder away from the 
blade holder.  
19. Clean out any remaining junk by pushing it down to the side/bottom of the cryostat, 
but wipe out the junk while it is frozen before turning off the cryostat for an 
extended period of time. 
20. Lay slides on a flat surface. 
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21. Using a spray bottle, spray 60˚C distilled water on slides to remove bubbles and 
promote the section adherence to the slide. Do not dip slides in water or saturate 




1. If sectioning becomes inconsistent and slices appear shredded, one of these 
methods may alleviate the problem: 
a. Allow the sample to freeze longer in the chuck holder on the left side of the 
cryostat. 
i. Use the “Freeze” button on the cryostat menu to allow the 
temperature of the chuck tray to drop to -40˚C. 
b. Try the sample later! 
c. The sample may not have been embedded fully. 
d. The blade may not be cold enough! Allow the cryostat to drop in 
temperature. 
e. Try a thinner or thicker sectioning depth. 
2. If you slice once or twice and nothing cuts, and on the third or fourth time you get a 
slice: 
a. The sample may not have been embedded fully. 




Appendix D Meniscus Safranin-O and Fast Green Stain Protocol 
 
Prepared Solutions 
• Weigerts Hematoxylin Working solution 
1. Mix equal parts of Part A and Part B 
• Fast Green FCF Solution 
1. Dissolve 0.1g fast green FCFR in 1000mL DI water 
• 1% Acetic Acid Solution 
1. Mix 10mL glacial acetic acid with 990mL DI water 
• 0.1% Safranin O Solution 
1. Dissolve 30mL Safranin O (1%) in 300mL DI water 
Set-Up: 











































































1. Place the slides in the slide holder. 
2. Stain with Weigert’s hematoxylin working solution for 10 minutes 
3. Place slides in DI water using 2 changes for 2 minutes each 
4. Stain with fast green (FCF) solution for 5 minutes 
5. Rinse quickly with 1% acetic acid solution for no more than 10 – 15 seconds 
6. Stain in 0.1% safranin O solution for 10 minutes 
7. Dehydrate and clear with 95% ethanol, absolute ethanol and xylene, using 2 changes 
each, for 2 minutes each 
 
Cleanup 
Weigerts, Safranin O and Fast green are saved. Filter using funnel and filter paper back into their 
containers (Weigerts must be placed in used container as it comes separated and is mixed to 





• Replace acetic acid wash every other round of staining. Replace first two ethanol washes 
after every round of staining. 
• Trouble shooting 
o If slides still have stain on them, plunge slide holder up and down during the 
acetic acid wash and ethanol/xylene clearings 
o If samples are falling off, relax slides additional times before staining, review 
slicing methods – if slices are not smooth and uniform I have found they come 
off easier  
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Appendix E GAG Coverage Analysis Protocol  
 
1. Open ImageJ  
2. From the images folder, drag an image into ImageJ 
3.  Under the Process tab, click “Subtract Background”  
4. Using the “Freehand Selection Tool” trace around the tissue 
a. Note: Leaving some white around the edges is ok  
b. Under the “Edit” tab click “Clear Outside”  
i. Rolling Ball Radius= 50 pixels  
ii. Check “Light background”  
5. Under “File” click “Save As” then “Tiff” , save this image in its respective folder 
in Desktop> Images  
a. Label the image as _Trim 
b. Example: M20_LLA_Trim 
6. If the Trim image is no longer open, open it and from the Image tab click “Color” 
then “Color Deconvolution”  
a. In the pop up menu, change H&E to “From ROI”, don’t check boxes, click 
“OK” 
b. In the “Color 1” pop up click “OK”  
c. Find the darkest red section on the tissue, draw a box around it without 
including any other colors, then right click to choose 
d. Again click OK and find the darkest blue section of the tissue, create box 
and right click 
e. Lastly create a box in the white background and right click  
7. 3 images will pop up, delete Color 3, it’s not needed 
a. Save Color 2 Image as “FG” for Fast Green, then close window   
i. Example: M20_LLA_Trim_FG 
b. Save Color 1 as “SafO” for Safranin O, keep window open  
i. Example: M20_LLA_SafO  
8. Have the Saf O image selected, then under the Image tab click “Adjust”, then 
“Threshold”  
a. Use the threshold tab to match the amount of red in the Saf O image to the 
Trim Image  
b. When accurate click apply  
9. Under the Analyze tab click “Analyze Particles”  
a. In the Analyze Particles Tab, the Pixel size should be “0-infinity”, the 
circularity is 0.0 - 1.0, and show “Nothing” 
i. “Display Results”, “Clear Results” and “Summarize” should be 
checked off 
b. Click OK  
10. Now select the Trim image, under the Image tab select “Type” then “8-bit”  
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a. Now “Adjust” and “threshold” again, however this time you want to get as 
many red pixels on the WHOLE tissue as you can, without making the 
background color red as well  
b. Repeat step 9, and in the Analyze Particles tab check off “Pixel Units”  
11. Record % Area Data in Excel sheet  
12. Save analyzed Trim and SafO images as: M20_LLA_Trim_T   and    
M20_LLA_SafO_R 
13. Move completed sample files to _Processed  
When a sample has two images:  
 
1. Drag each image into ImageJ and complete steps 3 & 4 for each image 
a. Save images as M20_RMP_1_Trim etc.  
2. While both images are still open go to Plugins>Stitching>deprecated>2D 
stitching  
a. For 1st reference image choose either “Sample_1_Trim” or 
“Sample_2_Trim”  
b. Choose the other image for 2nd register image 
c. Channel for 1st and 2nd should both be Red, Green, and Blue (RGB)  
d. Check use windowing and 5 peaks should be checked 
e. Check create merged image, method: linear blending, fusion alpha: 1.5, 
fusion image name can be whatever 
f. Check computer overlap, x:0 and y:0 
g. Click ok and remove any black area using clear outside function  
3. Save image as M20_RMP_Combined  






Appendix F Promega TUNEL Protocol 
 
NOTE: This SOP has been specifically tailored for OCT embedded tissue sections. 
This protocol will not work for paraffin embedded tissue sections or cell culture. See 
Promega protocol.  
Material  Location 
Promega TUNEL DeadEnd Kit  Small freezer in lab (bottom drawer) 
Tissue Samples on slides Small freezer in lab  
1x PBS  Countertop 
Propidium Iodide (PI) in PBS solution 15mL tube covered in foil in fridge  
Proteinase K solution Under fume hood  
4% formaldehyde in 1x PBS Under fume hood 
2X SSC solution Under fume hood  
DI water Counter top 
Incubator  Counter top 
Coplin jar Histology supply cabinet (next to 
fume hood) 
Cover slips Histology supplies drawer 
VectaShield Black box in fridge  
Pipettes  Counter top 
Pipette tips  Counter top 
 
Procedure  Time  
1. Turn on Incubator to 37C and 0% CO2  
2. Wash slides in 1x PBS  5 min  
3. Fix tissues in 4% formaldehyde in 1x PBS 15 min  
4. Rinse  in 1x PBS 5 min  
5. Rinse  in 1x PBS 5 min  
6. Pipette 50uL of 20ug/mL of Proteinase K solution 2 min 
7. Rinse in 1x PBS in Coplin jar 5 min 
8. Fix tissues in 4% formaldehyde in 1x PBS 5 min 
9. Rinse in 1x PBS  5 min 
10. Tap off excess liquid  
11. Pipette 50uL Equilibration Buffer  
MUST WORK WITH LIGHTS OFF FROM THIS STEP 
FORWARD 
12. Thaw Nucleotide Mix and rTdT on ice 
13. Create rTdT buffer solution:  
14. One rxn per slide  
10 min 
15. Remove excess Equilibration Buffer  
16. Pipette 35uL of rTdT incubation buffer onto tissues  
17. Cover slide with glass cover slip and place incubator  1 hour  
18. Carefully remove cover slip   
19. Pipette 50uL of 2X SSC to terminate rxn  15 min 
20. Rinse in 1x PBS  5 min 
21. Rinse in 1x PBS 5 min 
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22. Rinse in 1x PBS 5 min 
23. Pipette 50uL of PI solution  10 min 
24. Rinse in DI water 5 min 
25. Rinse in DI water  5 min 
26. Rinse in DI water 5 min  
27. Add SMALL drop of VectaShield   
28. Image using Fluorescence Microscope 
Green fluorescence at 520±20nm (Apoptotic Cells) 







Appendix G Cell Counting Protocol 
 
1. Open FIJI ImageJ 
2. Open both Live and Dead images of the same tissue  
a. Or Green and Red fluorescence for TUNEL, see note below 
3. Stitch both images together 
a. Plugins → Stitching → Pairwise Stitching → OK on both pop up screens  
4. Rotate image to make cropping easier 
a. Image → Transform → Rotate → Change angle and select preview box  
5. Select the rectangle tool and enclose as much of the tissue as possible in the rectangle 
6. Crop images  
a. Image → Crop 
7. Save image as “FILE NAME_TRIM” 
8. Filter image by color  
a. Image → Color → Split Channels 
i. For dead, keep red channel and save as “FILE NAME_TRIM_D” 
ii. For live, keep green channel  and save as “FILE NAME_TRIM_L” 
iii. Delete blue channel image 
9. Open original image  “FILE NAME_TRIM” to use as reference for following steps  
10. Convert both Images to 16 bit grayscale images  
a. Image → Type → 16-bit  
11. Threshold Images to remove background noise 
a. Image → Adjust → Threshold  
b. There are two sliders:  
i. The bottom slider should be set to 255 (or max of the scale) 
ii. The top slider can be adjusted to remove as much background as possible 
while keeping most of the cells 
c. Hit “Apply”, Image should now have white background with black dots (cells) 
12. Identify cell size  
a. Using the “Circle” cursor, draw a circle around the smallest cell in the image  
b. Press “m” a new window should pop-up telling you the size (pixel^2) of the 
circle you drew, record for later use 
13. Count cells  
a. Analyze → Analyze Particles  
b. In “Analyze Particles” window  
i. Change “Size (pixel^2)” to the size measured earlier to Infinity (ex. 55-
Inifinity is what I most commonly use)  
ii. “Circularity” should be 0.00-1.00 
iii. “Outlines” to show all cells being counted  
iv. Check boxes “Clear Results”. “Summarize”, and “Add to Manager” 
v. Hit “OK”  
14. Summary Window will pop-up, record the “Count” for the image  
a. Make sure the new image is counting the cells in your image 
15. Repeat for other image (live or dead) 
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16. Cell Viability tracking 
a. In “Excel”  
b. Track sample name, # Dead, # Live, Total Cells (Live+Dead) and Percentage 
((Live/Total)*100) in different columns  
NOTE: For TUNEL  
1. Green Image represents “Apoptotic Cells” 
2. Red Image represents “All dead cells” 




Appendix H MTS Power Up and Warming Up Protocol 
 
1) Turn on the monitor then the digital controller (Figure 1) 
a) The switch is on the back left of the FlexTest40 
 
 
Figure 1. MTS Computer, Monitor and Controller Box set-up 
 
2) Turn bottom right switch on front of MTS from “Turtle” mode to “Rabbit” mode 
(Figure 2) 









Figure 2. Front switches of MTS. Left switch locks and unlocks crosshead. Middle switch 
moves crosshead up and down, when unlocked. Bottom right switch indicates turtle or 
rabbit mode. Large red button is emergency stop button. 
 
3) Open “Station Manager” from Desktop  
4) Open the normal configuration (10580179.cfg) and choose appropriate load cell 
from the menu on the bottom left of the pop-up window (Figure 3) 
 
Figure 3. Selecting appropriate configuration and load cell for experiments  
 






Figure 4. Left hand panel of Station Manager when opened.  
 
6) Turn on the hydraulic pump (HPU-J25) by clicking the buttons with the levels   
a) It is important to go in order of Level 1, 2, and 3. Make sure the previous 
level glows yellow before moving on to the next level (Figure 4) 
7) Repeat similar process as Step 6 for the actuator (HSM-J28) (Figure 4) 
8) Move actuator to 0 using manual control, turn off manual control (Figure 5)  
a) Make sure to turn off manual control after using each time 
 
 
Figure 5. Manual Command window. When “Enabled” is on, user can manually move 
actuator up and down using “Axial Displacement” or spin using “Torsion”  
 
9) To warm-up the machine, in Function Generator (top left) (Figure 6), create a 
warmup using an amplitude similar to that being used in the real test and at 1 Hz 
for 10 minutes 
a) Wave shape: Sine 






Figure 6. Function Generator screen to warm-up MTS 
 
10) Press play button to start the warmup  
11) Redo warmup using half the previous amplitude and frequency, again for 10 
minutes 
12)  After roughly 20 minutes, warm-up is complete  
13) Switch to MPT (Dog Bone Icon with Computer on Station Manager) and open the 





Appendix I Meniscus Indentation – Relaxation using MTS Protocol  
 
Steps for Setting up Fixture on MTS  
1. Attach X-Y plate adapter to lower load cell 
2. Attach X-Y plate to X-Y plate adapter (smaller bolts 4) 
3. Attach Camera Mount to Camera Mount Adapter Plate  
4. Attach Camera Mount Adapter Plate to X-Y Plate (larger bolts 4) 
5. Attach Water Bath Adapter Plate to Camera Mount 
6. Attach Water Bath to Water Bath Adapter Plate 
 
 
Figure 1. Lower Set Up for Indentation Testing 
 
7. Attach 2 and 10 lb. Adapter Plate to the actuator 
a. Follow tightening instructions on coupler 
8. Attach Adapter Block for 2lb. Load Cell 
 
Set-up MTS Software and Warm-Up Machine  
1. Refer to MTS Power-Up and MTS Warm-Up Protocols for these steps   
 
Steps for Specimen Preparation 
1) Lay out ½ Drop Cloth, Gauze, Test Tubes, Test Tube Rack, Disposable Pipets, Low Temp 
Freeze Vials, Tape, Marker, Camera on dissection table 
2) Put roughly 3mL of 1x PBS in 12 15mL conical tubes 
a) Label the screw cap of each tube LLA, LLC, LLP, LMA, LMC, LMP, etc.  
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3) Remove specimens from packaging 
4) Label Drop cloth with specimen name, limb, and hemijoint 
5) Take photos of meniscal tissue as received laid by label  
6) Using tweezers and scalpel remove excess synovial tissue 
7) Take another photo of specimen  
a) Be sure to highlight any damage 
b) May need to take a photo of back few if damage is extensive 
i) Be sure to re-label if necessary 
8) Section menisci  
a) Can do all sectioning at once or as you go – doing all at once is easier 
b) Will need anterior, central, and posterior regions for both lateral and medial  
c) Lateral posterior is a more ligamentous attachment so be sure to leave meniscal 
tissue when sectioning 
 
 
Figure 3. Meniscal Sectioning 
9) Repeat for both joints 
10) Place specimens in respective conical tube and put in ice until testing 
 
Testing 
1) Stop warm-up and switch to MPT 
2) Be sure Procedure is set to “DOD_Indentation” can be found in Procedures → Gerardo 
3) Attach 2lb. Load Cell 
a) Take note of how the load cell cable is attached to MTS 
i) When removing take special care  
(1) Hold square part of cable adjustments steady 
(2) Turn cylindrical part clockwise 
4) Attach Load Cell to Indenter Adapter 
5) Attach Indenter Tip (Just leave sitting beside if setting up a day early) 





Figure 2. Upper Set Up for Indentation Testing (note this image was during testing and thus 
includes the wedge mount with specimen attached) 
 
6) Clean wedge using razor blade to scrape off left over glue remnants 
7) Place small amount of super glue on wedge mount 
8) Place Specimen near top edge trying to get specimen face as “flat” as possible 
9) Attach wedge to water bath 
10) Fill water bath with PBS 
a) Be sure valve is closed 
b) Fill slightly over wedge but not far enough over that PBS will come in contact with 
nut on indenter when testing 
11) Adjust crosshead so specimen will not bottom out if hydraulics are lost  
12) Create new Specimen  
a) Label Ex. “BBGB4_LLA”  , HIT ENTER 
(a) ****Very important to label this way when using my MATLab code to 
process  
13) Lower indenter tip till just in water 
14) Adjust X-Y plate to get specimen perpendicular to inventor tip and indenter tip is 
located over thickest part of specimen  
15) Lower indenter tip till just above specimen 
16) Zero out Axial Force 2 
17) Apply 20mN force to specimen 
18) Disable manual controls 






Figure 4. Indentation Alignment 
 
Test Done – Specimen Removal  
1. Create new Specimen 
2. Manually enable controls 
3. Raise up actuator 
4. Remove wedge mount 
5. Using razorblade carefully remove specimen 
a. Will need to remove all superglue 
i. If care is taken you can “pop” off specimen with razor bade 
ii. Alternatively once off wedge, can use scalpel to scrape off leftover 
superglue 
6. Place specimen in corresponding PBS filled test tube 
7. Repeat Testing for all samples 
 
All Testing Done – Shut Down 
1. Be sure when hydraulics are turned off and actuator drops to -50mm it would hit 
anything 
a. Adjust crosshead if necessary  
2. Disable Hydraulics  
a. HSM1 & HPU Off 
3. Close Station Manager 
4. Turn off controller and record Pump Time 
5. Create Folder in “Specimens” file found on desktop for animal(s) tested that day  
a. Label Ex. “BBGB4” 





Appendix J Bruker Skyscan 1276 µCT - Scanning Protocol 
 
Note - This protocol is intended for Flemish giant rabbit femurs and tibias. Depending on 
sample being scanned, different voxel size may need to be used.  
 
1) Log in to the computer, the password is brukerct 
 
2) Open Skyscan 1276 software and click the radiation button 
a) The machine takes 15 minutes to warm-up 
 
3) Insert parameters on the bottom left of the screen 
a) Al-Cu filter  
b) 2016x1344 
 
4) Load Std Res file by opening Options, configurations, load, std 
 
5) Turn off x-ray to open scanning bed and insert the first sample, create a folder with 
sample name  
 
6) In Actions menu, press Scout + batch scan, can press cancel once past area of interest 
 
7) Click on Grab button (TV icon) then double click on the sample on the scout screen 
to the left 
 
8) Right-click in the main window, make sure min transmission is about 30% 
a) If not, can increase voltage and current in Scanning Modes page 
 
9) Go up to roughly y=0 by double-clicking on scout screen and turn flat field off by 
double-clicking ff icon 
 
10)  Press Shift-Alt-Ctrl-S to unlock modes 
 
11)  Under the Options menu, select Scanning Modes 
a) Change exposure for correct parameters to bring average transmission to 60% 
 
12)  Turn flat field back on and update the flat field in the options menu 
 
13)  Redo Scout and Batch scan, can cancel once past sample 
a) If the scout scan appears very white, it is because the hi-res setting was loaded 
i) Go to the options menu, click on load and select std res file 
ii) Check to make sure parameters and transmissions are correct 
 
14)  Control-click and drag from just above bone to just below the bone 
 
15)  Add to oversized batch, insert correct name and file location 
 
133 
a) Select X-ray off after scanning and 360 Scanning  
 
16)  Start Scan 
 
17)  Once complete, delete the previous scan from batch and oversize scanning window 
 
18)  Remove sample from scanning bed and mark as scanned  
 
19)  Repeat, there is no need to change any parameters unless rebooting software or 




Appendix K Bruker NRecon - Reconstruction Protocol 
 
1) Open NRecon software, click action and open desired dataset 
 
2) Click and open an image with a number in the name (Just not one of the first 5 or so) 
 
3) Drag outer limits (red lines on the screen) to just above and below the sample, drag 
center line to the primary area of interest 
 
4) On settings tab to the right, change misalignment compensation to 0  
 
5) On start tab, click fine-tuning 
a) Post alignment 
b) 5 Trials 
c) 1.0 Step 
 
6) Fine-tune, then find the clearest image 
a) Scroll through the five new trials (-2, -1, 0, 1, 2), the clearest of the five will be 
your new reference image  
 
7) In output tab, change min to 0 and max to .027 
a) This number is for Flemish Giant rabbit bones for the DOD study, for different 
studies, it is crucial to use the same numbers for your scale  
 
8) Fine-tune again with same parameters, again finding the clearest image and add it to 
batch on the start tab 
 
9) If running multiple samples in one large batch, select “Add to Batch” and then open a 
new sample to reconstruct and repeat steps 1 - 8 
a) If not running in a batch, select “Start”  
 




Appendix L Bruker CTAn – Trabecular Bone Analysis Protocol 
 
Note – this protocol is intended for the Flemish Giant rabbit femurs and tibias in the 
DOD project (2017-2021). Steps may need to be changed to suit different study needs.  
 
1) In original sample folder (outside of the Reconstruction folder) create five new 
folders  
a) VOI 
b) Lateral_Uncovered  
c) Lateral_Covered 
d) Medial_Uncovered 
e) Medial_Covered  
f) These folders will be used later to save images/data 
 
2) Open reconstructed file in DataViewer Software  
 
3) In DataViewer, select “Allow Projections in 3D Viewing”  
 
4) Holding SHIFT, reorient bone so that is it parallel 
a) Let the software re-orient, takes a few seconds 
 
5) Select the Volume of Interest (VOI) 
a) Actions → Draw/Save Multiple Volume of Interest(VOI) 
 
6) Blue boxes will show up in all three different views 
a) Resize the highlighted box to fit the VOI 
b) Top: Small space above tallest point of bone  
c) Bottom: Small space below the growth plate (physeal scar) 
 
7) Move scale bar through depth of tissue to ensure area between top of bone and 
growth plate are within the box  
 
8) In DataViewer Software, save the VOI into the “VOI” folder created in Step 1 
a) Make sure to save top down view (might be coronal or transverse depending on 
scan orientation) 
 
9) Open the newly saved VOI in CTAn  
 
10) Scroll through the “Raw Images” and find the Image that shows the full tibia with 
cortical bone  
 
11) Set this as your top image  
a) Right click on the Z-Position → “Set the Top of Selection” 
b) RECORD this number on the Google Doc titled “CTAn Bone Tracking”  
 
12) Find and set the bottom image  
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a) We will be imaging 90 slices from the top to bottom (~2mm depth)  
b) Add or Subtract 90 from the Top Image Z-position  
i) Add if orientated tibial plateau down  
ii) Subtract if orientated tibial plateau up  
 
13) Select “Regions of Interest Preview” tab 
 




Width - 340, Height - 321  
Lateral Covered:  
Width - 212, Height - 218 
Medial Uncovered:  
Width - 215, Height - 358 
Medial Covered:  
Width - 187, Height - 223 
Tibia 
Lateral Uncovered: 
Width - 162, Height - 240  
Lateral Covered:  
Width - 181, Height - 77 
Medial Uncovered:  
Width - 205, Height - 310 
Medial Covered:  
Width - 201, Height - 121 
*All values converted to Pixels, if interested in mm, multiply pixel size by voxel size 







15) Align the edges of the box with cortical bone image  
a) See picture to determine placement  
 
16) Determine coordinate of corner  
a) RECORD x and y values in “CTAn Bone Tracking” 
b) Select “Measure angle, distance or path” → “Coordinate” → Click on corner of 
interest on the ROI box → Write down  
c) CTAn Bone Tracking will automatically convert mm (given) to pixel 
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i) If interested, 1mm = 50 pixels, so multiply coordinate number by 50 
 
17) Repeat steps 14-16 for the remaining three ROIs 
a) Change dimensions of box for next ROI 
 
18) Once all coordinates have been determined, create a circle shaped ROI 
a) Width - 80, Height - 80  
b) 80 pixels corresponds to 1.6mm diameter, the same size as the indenter tip used to 
determine the mechanical properties of articular cartilage at MSU 
 
19) Using known coordinates for the locations of interest, change the center of the circle 
ROI to one of the four locations 
 
20) Once the circle ROI is on the right location, select “Save new Dataset from ROI”  in 
its appropriate folder created in Step 1  
a) Save Images from ROI window → Location → Browse → Select appropriate 
folder 
 
21) “Binary Selection Preview” tab 
a) This will create the data into black and white images in order to analyze  
 
22) Threshold the data 
a) Histogram tab → select “Automatic Thresholding” 
 
23) Start Analyzing - “Morphometry preview” tab 
a) Analysis tab → “3D” analysis  
b) Save data 
c) 3D analysis tab  
i) Check:  
(1) Basic Values  
(2) Additional Values 
(3) Structure Model Index 
(4) Trabecular Thickness 
(5) Trabecular Separation  
d) Continue  
e) Save the text file in appropriate folder  
 




Appendix M Bruker CTAn – Cortical Bone Analysis Protocol 
 
Note – this protocol is intended for the Flemish Giant rabbit femurs and tibias in the 
DOD project (2017-2021). Steps may need to be changed to suit different study needs.  
 
1) Create a “Lateral Cortical” and “Medial Cortical” folder within the main folder of the 
bone being analyzed  
 
2) Open cortical VOI of desired bone in CTAn 
 
 
3) Choose a 50 slice chunk in the middle of the bone and set upper and lower bounds  
 
4) On the same slice, take 5 thickness measurements from the middle of both lateral and 
medial condyles. Enter into the spreadsheet. 
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5) At the top of the selected VOI, create a rectangular ROI on the cortical bone of either 
condyle. Edit ROI every 10 slices through entire VOI 
 
 
6) In binary selection, match up as best as possible with the raw image. Save histogram 





7) Run the 3D analysis, making sure porosity is selected from the additional values. 
Save resulting file in the appropriate folder 
 




Appendix N Bruker CTAn – Osteophyte Bone Volume Analysis Protocol 
 
Note – this protocol is intended for the Flemish Giant rabbit femurs and tibias in the 




Shift + Right-Click Adds area to ROI 
Shift + Left-Click Creates new ROI, will delete any existing ROI on the slice 
Cntrl + Right-Click Deletes any selected area from ROI 
 
1) Open Trabecular VOI folder of desired bone in CTAn 
 
2) Starting from the top of the scan (condyles), go down 10 mm or 500 slices and set top 
and bottom of VOI 
 
 
3) Go down to the bottom of the selection (shaft) and begin highlighting all bone and 
osteophyte while leaving out any of the greyish potting material.  
 
 




5) Once done, save this VOI in the “osteophyte” folder and open VOI in CTAn 
 
6) Create another VOI but this time only highlight the actual bone and none of the 
osteophyte tissue 
 
7) Edit this VOI every 10 slices 
 
 
8) Once done, select the subtractive VOI bottom 
 
 














Appendix O CaptureSelect Multispecies Albumin Depletion Protocol 
 
1. Thaw synovial fluid sample on ice (~30 minutes) 
 
2. While sample thaws, prep depletion spin column 
 
3. Load 200uL of CaptureSelect Multispecies Albumin depletion product into spin 
column 
 
4. Wash and hydrate the resin by loading 500uL of 1x PBS 
 
5. Remove the twist off tip at the bottom of spin column and place in an empty 2mL 
capture tube  
 
6. Centrifuge at 3000 rpm (700 xg) for 1 minute  
 
7. Discard flow through PBS  
 
8. Repeat steps 4-7 two more times  
 
9. Once sample is thawed, load 200uL of sample into the depletion spin column 
 
10. Move depletion spin column into a new 2mL conical tube  
 
11. Incubate for 20 minutes and vortex every few minutes 
 
12. Collect flow through by centrifuging spin column at 3000 rpm for 1 minute  
 
13. Rinse spin column with 100 uL of 1x PBS, centrifuge at 3000 rpm for 1 minute 
and collect flow through in the same tube  
 
14. Repeat step 13 two more times  
 




Appendix P Preliminary Synovial Fluid Work 
 
First Run – High Select MARS-14 Mini Spin Columns 
 
The first attempt of performing proteomic analysis of the synovial fluid used the 
High Select Top 14 Abundant Protein Depletion Mini Columns from Thermo Fisher 
(A36369). Unfortunately, these samples were run prepared with chemicals and laboratory 
equipment (i.e. pipette tips, conical tubes, plastic ware) that were not graded to be used 
for mass spectrometry. This led to large plastic contamination.  
The initial volume of 10uL of raw samples was too small to begin with, by the 
end of the sample preparation process, samples had very low protein concentrations. 
These low concentrations made the issue of plastic contamination much more severe and 
which greatly affected the proteins found using mass spec. Due to the COVID-19 
pandemic, there was a six-month period in which no new trials for proteomic analysis 
were conducted (February 2020 to August 2020).  
 
Synovial Fluid Sample Prep – Run 1 SOP 
 
Determine Protein Concentration – BCA Assay 
1. Prepare standards and working reagent for the Micro BCA Protein Assay Kit prior 
to starting the rest of protocol  
2. Thaw samples to room temp   
3. Transfer SF to 1.5mL tube and centrifuge at 2000 rpm for 10 min and keep 
supernatant 
4. While samples are in the centrifuge, load 150 uL (in duplicate) of each standard 
into a 96 well plate 
5. Remove samples from centrifuge and move supernatant to a new -80 tube 
6. Load 150uL of sample (in duplicate) into 96 well plate – record which well each 
sample is loaded onto  
7. Put samples in fridge until Step 2 (page 2) 
8. Add 150uL of working reagent to each well and mix plate on shaker plate for 30 
seconds  
9. Cover plate with parafilm and incubate at 37C for 2 hours 
10. While plate incubates, prepare plate reader (located in microscopy room) by 
loading the Micro BCA Assay Protocol  
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11. In SpectraMax Software, label plate with appropriate labels for wells containing 
sample  
12. Following incubation, cool plate to room temperature  
13. Measure the absorbance of the plate at 562nm  
14. Subtract the average 562nm absorbance reading from the Blank standard 
replicates from the 562nm reading of all other individual standard and unknown 
sample replicates  
15. Prepare a standard curve by plotting the average corrected reading for each BSA 
standard vs its concentration in ug/mL.  
16. Use the standard curve to determine the protein concentration of each unknown 
sample.  
 
Mini Spin Column Methods 
1. Thaw samples to room temp. 
2. Centrifuge SF sample at 2000 rpm for 10 min and keep supernatant. 
3. Run SF through MARS-14 mini spin column to deplete top 14 abundant 
proteins  
a. Equilibrate the depletion spin column to room temperature.  
b. Remove the column screw cap and add 10µL of SF directly to the resin 
slurry in the column.  
c. Cap the column and invert the column several times until the resin is 
completely suspended in the solution.  
d. Incubate the mixture in the column with gentle end-over-end mixing for 
60 minutes at room temperature.  
e. Make sure the sample mixes with the resin during the incubation period. 
Alternatively, vortex every 5 minutes.  
f. Twist off the bottom closure and loosen the cap.  
g. Place column into a 2mL collection tube and centrifuge at 1000 × g for 2 
minutes. 
h. Discard the column containing the resin.  
 
Methods for Alkylation and Reduction 
1. Add 15µL of Digestion Buffer and 1.5µL of Reducing Buffer to a 0.5mL 
microcentrifuge tube. 
2. Add ≤ 10.5µL of SF to the tube and adjust the final volume to 27µL with 
ultrapure water. 
3. Incubate sample at 95°C for 5 minutes and allow to cool. 
4. Prepare alkylation buffer. 
5. Add 9mg of Iodoacetamide (IAA) to a foil wrapped tube. 
6. Add 500µL of ultrapure water to the IAA. (conc ~100mM) 
7. Add 3µL of Alkylation Buffer to the tube and incubate in the dark at room 
temperature for 20 minutes. 
 
Methods for In-Solution Trypsin Digestion 
1. Prepare activated trypsin. 
2. Create Trypsin Stock. 
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a. Add 20µL of Trypsin Storage Solution to the vial containing 
lyophilized Trypsin Protease. 
b. Divide solution into four separate tubes with ~5µL each. 
c. Store at -20°C. 
3. Thaw a Trypsin Stock aliquot on ice.  
4. Dilute stock 10-fold by adding 45µL of ultrapure water for a final 
concentration of ~100ng/µL). Store this solution at -20°C for up to two 
months. 
5. Add 1µL of Activated Trypsin to the reaction tube and incubate at 37°C for 3 
hours. 
6. Add an additional 1µL of Activated Trypsin to the reaction tube and incubate 
at 37°C for 2 hours. 
 
Methods for Guanidination 
1. The digested sample may be divided at this time to provide a no guanidination 
control, or the entire digest may be guanidinated.  
2. To divide digest, place 16µL of the digest to a new tube and label as no 
guanidination control.  
3. To the remaining digest add 16µL of ultrapure water.  
4. Add 10µL of Ammonium Hydroxide to the digest and vortex to mix well. 
5. Create Guanidination Reagent. 
a. Dissolve 50mg of O-Methlyisourea hemisulfate in 51µL of ultrapure 
water. 
b. Final volume will be ~80µL. 
c. Store excess at -20°C. 
6. Add 6µL of Guanidination Reagent and vortex to mix well.  
7. Incubate sample at 65°C for 12 minutes.  
8. Add 3µL of Trifluoroacetic acid to stop reaction, or proceed directly to sample 
preparation appropriate for downstream analysis. 
9. The stopped rxn may be stored at -20°C for an extended period. 
 
Methods for Cleaning Samples 
1. Prepare conditioning/washing solution by adding 2µL of TFA to 2mL of 
ultrapure water 
2. Prepare the elution solution by combining 2µL of TFA, 1mL of water, and 
1mL acetonitrile in a tube 
3. Prepare TMT washing solution by adding 50µL of methanol and 1µL of TFA 
to 950µL of ultrapure water and mix 
4. Remove white tip from the bottom column and discard 
5. Place column in 2mL microcentrifuge tube and centrifuge at 5,000g for 1 min 
and discard liquid 
6. Remove top screw cap and add 300µL ACN and replace cap 
7. Centrifuge at 5,000g for 1 min in 2mL microcentrifuge tube 
8. Discard ACN and repeat wash step 
9. Wash spin column twice with 0.1% TFA in water as described in steps 6-8 
10. Dissolve 5µg of sample in 300µL of 0.1% TFA in water 
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11. Place in 2mL microcentrifuge tube and load 300µL of the sample in solution. 
12. Replace cap, centrifuge at 3,000g for 1 min, and discard flow through 
13. Load 300µL 0.1% TFA in water into column and centrifuge at 3,000g for 1 
min 
14. Discard eluate and repeat this step 2 more times 
15. Wash column with 300µL of TMT washing solution twice as described in step 
13 
16. Place column in new 2mL microcentrifuge tube, load 300µL of elution 
solution, and centrifuge at 3,000g for 1 min  
17. Add another 300µL of elution solution and centrifuge at 3,000g for 1 min 




Second Run – High Select MARS-14 Midi Spin Columns 
 
The second attempt of performing proteomic analysis of the synovial fluid used the High 
Select Top 14 Abundant Protein Depletion Midi Spin Columns from Thermo Fisher 
(A36371). For this trial, mass spectrometry grade reagents, chemicals, and plastic ware 
were used to decrease the number of plastic contaminants in the samples. Midi spin 
columns were used for this step, in order to increase the initial amount of raw sample 
used from 10uL to 100uL. Following the advice from the UMass Mass Spec CORE 
Facility, two extra washing steps were included in the desalting column prep prior to 
samples being loaded to ensure any plastic contaminants from these tubes were not also 
affecting our outcomes.  
During this trial, there were low amounts of plastic contaminants found in the 
samples. However, large amounts of proteins that were supposed to be depleted by the 
spin column were still present. This indicated that the spin column was not ideal to be 
used for rabbit samples.  
 
Synovial Fluid Sample Prep – Run 2 
  
All steps from Run 1 were similar, except for the use of the Midi Spin Column instead of 
the Mini Spin Columns and the Guanidinatio step was skipped. 
Methods for Depletion – Midi Spin Column 
1. Thaw samples to room temp. 
2. Centrifuge SF sample at 2000 rpm for 10 min and keep supernatant. 
3. Run SF through MARS-14 midi spin column to deplete top 14 abundant 
proteins  
a. Equilibrate the depletion spin column to room temperature.  
b. Remove the column screw cap and add 100µL of SF directly to the resin 
slurry in the column.  
c. Cap the column and invert the column several times until the resin is 




d. Incubate the mixture in the column with gentle end-over-end mixing for 
60 minutes at room temperature.  
e. Make sure the sample mixes with the resin during the incubation period. 
Alternatively, vortex every 5 minutes.  
f. Twist off the bottom closure and loosen the cap.  
g. Place column into a 15mL collection tube and centrifuge at 1000 × g for 2 
minutes. 
h. Discard the column containing the resin.  
 
Methods for Cleaning Samples 
1. Prepare conditioning/washing solution by adding 2µL of TFA to 2mL of 
ultrapure water 
2. Prepare the elution solution by combining 2µL of TFA, 1mL of water, and 
1mL acetonitrile in a tube 
3. Prepare TMT washing solution by adding 50µL of methanol and 1µL of TFA 
to 950µL of ultrapure water and mix 
4. Remove white tip from the bottom column and discard 
5. Place column in 2mL microcentrifuge tube and centrifuge at 5,000g for 1 min 
and discard liquid 
6. Remove top screw cap and add 300µL ACN and replace cap 
7. Centrifuge at 5,000g for 1 min in 2mL microcentrifuge tube 
8. Discard ACN and repeat wash step 
9. Wash spin column twice with 0.1% TFA in water as described in steps 6-8 
10. Dissolve 5µg of sample in 300µL of 0.1% TFA in water 
11. Place in 2mL microcentrifuge tube and load 300µL of the sample in solution. 
12. Replace cap, centrifuge at 3,000g for 1 min, and discard flow through 
13. Load 300µL 0.1% TFA in water into column and centrifuge at 3,000g for 1 
min 
14. Discard eluate and repeat this step 2 more times 
15. Wash column with 300µL of TMT washing solution twice as described in step 
13 
16. Place column in new 2mL microcentrifuge tube, load 300µL of elution 
solution, and centrifuge at 3,000g for 1 min  
17. Add another 300µL of elution solution and centrifuge at 3,000g for 1 min 





Third Run – Albumin Depletion Product and Tandem Mass Target Labeling  
 
For the third attempt, a MultiSpecies Albumin Depletion product (191085310) 
from Thermo Fisher was used along with Tandem Mass Target labeling. The 
manufacturer suggested this product as previous clients had used it to remove albumin 
from rabbit samples. Since the end goal was to quantify and receive a ratio of proteins 
expressed between the treated (right) and control (left) limbs, samples were labeled for 
Tandem Mass Target (TMT).  
The outcomes of this trial showed that the albumin depletion product was 
successful in removing large amounts of the protein in the samples. Unfortunately, the 
desalting columns used for this run were not compatible with the TMT labels. This meant 
that only proteins without TMT labels were used for proteomic analyses making it 
impossible to determine which proteins came from which sample.  
Synovial Fluid Sample Prep – Run 3 SOP 
 
Determine Protein Concentration – BCA Assay 
1. Prepare standards and working reagent for the Micro BCA Protein Assay Kit prior 
to starting the rest of protocol  
2. Thaw samples to room temp   
3. Transfer SF to 1.5mL tube and centrifuge at 2000 rpm for 10 min and keep 
supernatant 
4. While samples are in the centrifuge, load 150 uL (in duplicate) of each standard 
into a 96 well plate 
5. Remove samples from centrifuge and move supernatant to a new -80 tube 
6. Load 150uL of sample (in duplicate) into 96 well plate – record which well each 
sample is loaded onto  
7. Put samples in fridge until Step 2 (page 2) 
8. Add 150uL of working reagent to each well and mix plate on shaker plate for 30 
seconds  
9. Cover plate with parafilm and incubate at 37C for 2 hours 
10. While plate incubates, prepare plate reader (located in microscopy room) by 
loading the Micro BCA Assay Protocol  
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11. In SpectraMax Software, label plate with appropriate labels for wells containing 
sample  
12. Following incubation, cool plate to room temperature  
13. Measure the absorbance of the plate at 562nm  
14. Subtract the average 562nm absorbance reading from the Blank standard 
replicates from the 562nm reading of all other individual standard and unknown 
sample replicates  
15. Prepare a standard curve by plotting the average corrected reading for each BSA 
standard vs its concentration in ug/mL.  
16. Use the standard curve to determine the protein concentration of each unknown 
sample.  
 
CaptureSelect Multispecies Albumin Depletion Protocol 
16. Load 100uL of CaptureSelect Multispecies Albumin depletion product into spin 
column 
17. Wash and hydrate the resin by loading 500uL of 1x PBS 
18. Remove the twist off tip at the bottom of spin column and place in an empty 2mL 
capture tube  
19. Centrifuge at 3000 rpm (700 xg) for 1 minute  
20. Discard flow through PBS  
21. Repeat steps 4-7 two more times  
22. Once sample is thawed, load 100uL of sample into the depletion spin column 
23. Move depletion spin column into a new 2mL conical tube  
24. Incubate for 20 minutes and vortex every few minutes 
25. Collect flow through by centrifuging spin column at 3000 rpm for 1 minute  
26. Rinse spin column with 100 uL of 1x PBS, centrifuge at 3000 rpm for 1 minute 
and collect flow through in the same tube  
27. Repeat step 13 two more times  
28. Sample is ready for further steps  
 
Methods for Alkylation and Reduction  
1. Create Reducing buffer by adding 500 uL of ultrapure water to a 7.7mg tube of 
DTT for a final concentration of 100mM 
- Store in glass vial at -20C  
2. Create Alkylation buffer by adding 9mg of IAA to 500uL of ultrapure water for 
final concentration of 100mM  
- Store in glass vial at -20C  
3. Transfer 50uL of sample into a new 0.5mL tube (make sure to write down protein 
concentration in notebook)  
4. Add 15uL of Reducing buffer to each sample  
5. Incubate samples at 95C on a heat block for 5 minutes and allow to cool 
6. Add 11uL of Alkylation buffer to each sample and incubate in the dark at room 
temperature for 20 minutes  
 
Methods for Trypsin Digestion 
1. Add 150uL of SMART Digest buffer to the tube  
 
153 
2. Add 5uL of SMART Digest soluble trypsin  
3. Incubate samples overnight (8 hours) at 30C  
 
Methods for TMT Labelling  
1. Equilibrate the TMT Label Reagents to room temperature 
2. Add 41µL of anhydrous acetonitrile to each tube 
3. Allow the reagent to dissolve for 5 minutes with occasional vortexing 
4. Briefly centrifuge the tube to gather the solution 
5. Transfer 100uL of reduced and alkylated protein digest to the TMT Reagent 
vial 
a. Make sure to record which sample went into which TMT label tube 
6. Incubate the reaction for 1 hour at room temperature 
7. Add 8µL of 5% hydroxylamine to the sample and incubate for 15 minutes to 
quench the reaction 








Fourth Run – Pierce C18 Spin Columns  
 
For the fourth attempt, Pierce C18 Spin desalting columns (89873) were obtained 
from Thermo Fisher after consulting with the UMass Mass Spec CORE facility, the 
manufacturer, and the literature. These columns are compatible with the TMT labels 
being used for the study.  The results of the study showed that samples still had low 
labelling efficiency. This meant that proteins from each individual sample were not 
labeled efficiently, so during protein identification and quantification, after all ten 
samples were mixed into one tube for proteomic analysis, it was impossible to determine 
which proteins came from which sample. Ratios between treated and control limbs could 
not be obtained. Possible errors for this could be due to earlier sample preparation.  
After this trial, the UMass CORE Facility recommended that our group reach out 
to other Mass Spec CORE facilities who had more experience working with Synovial 
Fluid samples and could prepare the samples for us. After looking at potential options, we 
decided to work with the University of Connecticut Mass Spec CORE Facility.  
 
Synovial Fluid Fourth Run SOP 
All steps from the Third Run were used, but different desalting columns were used to 
clean the samples. Methods below: 
Methods for Sample Clean-Up using C18 spin column 
1. Create elution solution by adding 2uL of TFA, 1mL of ultra-pure water, and 1mL 
acetonitrile in a glass vial  
2. Condition the disk by pipetting 250uL of methanol through the C18 cartridge   
3. Centrifuge the disk at 1200rpm for 2 min in a 15mL conical tube 
- Make sure surface of disk remains wet    
4. Remove residual methanol by pipetting 500 uL of DI water  
5. Centrifuge the disk at 1200rpm for 2 min 
- Make sure surface of disk remains wet    
6. Load sample and centrifuge at 2500rpm for 2 min  
7. Load 500uL of DI water to remove unbinding proteins and centrifuge at 2500rpm 
for 2 min 
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8. Load 500uL of 5% ACN in DI water and centrifuge at 2500rpm for 2 min 
9. Move disk onto a new 15mL conical tube – next step will collect sample from 
tube  
10. Load 300uL of elution solution and centrifuge at 2500g for 2 min 
11. Transfer sample into a new 2mL tube and label  
12. Dehydrate samples using nitrogen gas in fume hood – takes roughly 1 hour  
13. Place dehydrated samples in the UMass Mass Spec freezer located in the hallway 





Fifth Run – Working with UConn Mass Spec CORE 
 
 Following the suggestion from the UMass Mass Spec CORE facility, our group 
began to work with the Mass Spec CORE facility at the University of Connecticut 
(UConn). For the fifth run, the UConn group was interested in determining the total 
amount of protein our samples contained by using the recommended raw sample volume, 
doubling it, and if using a hyaluronidase enzyme before or after the depletion column, 
would result in higher quality samples by removing more albumin.  
For this trial, two samples from the same animal and limb were prepared at 
UMass using the MultiSpecies Albumin Depletion product using two different volumes 
(100uL and 200uL) of the sample to determine if more product would be able to remove 
more albumin from the samples. Two more vials of the same sample (100uL and 200uL) 
were shipped to them along with the depletion product for UConn to determine if adding 
the enzyme before or after the depletion column affected the total number of proteins.  
The results from this trial run showed that doubling the initial volume of raw 
sample used provided us with the enough protein concentrations to confidently conduct 
the experiment. The results also showed that adding the hyaluronidase enzyme before or 
after the depletion product did not affect the outcome of protein concentrations. 
Therefore, moving forward, the following depletion product was used:  
 
CaptureSelect Multispecies Albumin Depletion Protocol 
1. Load 200uL of CaptureSelect Multispecies Albumin depletion product into spin 
column 
2. Wash and hydrate the resin by loading 500uL of 1x PBS 
3. Remove the twist off tip at the bottom of spin column and place in an empty 2mL 
capture tube  
4. Centrifuge at 3000 rpm (700 xg) for 1 minute  
5. Discard flow through PBS  
6. Repeat steps 4-7 two more times  
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7. Once sample is thawed, load 200uL of sample into the depletion spin column 
8. Move depletion spin column into a new 2mL conical tube  
9. Incubate for 20 minutes and vortex every few minutes 
10. Collect flow through by centrifuging spin column at 3000 rpm for 1 minute  
11. Rinse spin column with 100 uL of 1x PBS, centrifuge at 3000 rpm for 1 minute 
and collect flow through in the same tube  
12. Repeat step 13 two more times  





Sixth Run – Working with UConn Mass Spec CORE 
 Once it was established that each sample contained enough proteins to conduct 
the experiment, UConn began to move forward with the experiment. For the TMT 
analysis, 6-plex labels would be used to run 6 sets of 6 samples. For these labels, 1ug of 
each sample was needed to run the experiments in order to confidently say that the ratios 
obtained from the experiment between treated and control limbs were accurate.  
For the first mix (Mix 1), it was determined that the values were close to 1ug, but 
not as close as the UConn group would feel comfortable making conclusions with. It was 
unclear if there were label discrepancies or if the readings from the A280 NanoDrop were 
inaccurate.  
For the second mix (Mix 2), the group at UConn first determined the label 
efficiency was up to their standards and that the NanoDrop readings could be slightly off. 
The results gave protein values closer to 1 and made the UConn group more comfortable 
for our group to draw conclusions with. These samples were used in Chapter 5 of this 
dissertation.  
They suggested a final mix (Mix 3), in which total proteins in the sample would 
quantified using a Colorimetric Peptide Concentration Assay, instead of the A280 
NanoDrop. However, the protein values used in this study were not 1 or better than the 
values for Mix 2. This mix did account for the samples being from either the 1 month or 
6-month time point, so comparison of changes in protein expression over time in each 
treatment group could be made.  
 
